Engineered beta-subunit of tryptophan synthase for production of non-canonical amino acids

ABSTRACT

This disclosure relates to modified tryptophan synthase and more particularly to modified beta-subunits of tryptophan synthase. The disclosure further relates to cells expressing such modified subunits and methods of producing non-canonical amino acids.

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims priority under 35 U.S.C. 119 to U.S. ProvisionalApplication Ser. No. 62/144,783, filed Apr. 8, 2015, and U.S.Provisional Application No. 62/236,030, filed Oct. 1, 2015, thedisclosures of which are incorporated herein by reference.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH

This invention was made with government support under 1F32GM110851-01A1awarded by the National Institutes of Health. The government has certainrights in the invention.

INCORPORATION BY REFERENCE OF SEQUENCE LISTING

Accompanying this filing is a Sequence Listing entitled “sequenceST25.txt”, created on Apr. 8, 2016 and having 186 kB of data, machineformatted on IBM-PC, MS-Windows operating system. The sequence listingis hereby incorporated by reference in its entirety for all purposes.

TECHNICAL FIELD

This invention relates to modified tryptophan synthase and moreparticularly to modified beta-subunits of tryptophan synthase. Theinvention further relates to cells expressing such modified subunits andmethods of producing non-canonical amino acids.

BACKGROUND

Heteromeric enzyme complexes catalyzing a rich array of useful reactionsare often allosterically regulated by their protein partners, such thatthe catalytic subunits are much less active when isolated. Utilizingisolated enzyme subunits, however, is desirable for biosyntheticapplications, wherein expressing large complexes increases the metabolicload on the host cell and complicates efforts to engineer activity,substrate specificity, stability, and other properties.

Tryptophan synthase (TrpS; EC 4.2.1.20) is a heterodimeric complex thatcatalyzes the formation of L-tryptophan (Trp) from L-serine (Ser) andindole glycerol phosphate (IGP) (see, FIG. 1A). The mechanism of thistransformation has been extensively studied for TrpS from Escherichiacoli and Salmonella typhimurium, where it has been shown the enzymeconsists of two subunits, TrpA (α-subunit) and TrpB (β-subunit), both ofwhich have low catalytic efficiencies in isolation. The activities ofboth subunits increase upon complex formation and are further regulatedby an intricate and well-studied allosteric mechanism. IGP binding tothe α-subunit stimulates pyridoxal phosphate (PLP)-dependentaminoacrylate formation in the β-subunit [E(A-A); FIG. 1B], which inturn promotes retro-aldol cleavage of IGP in the α-subunit, releasingindole. This tightly choreographed mechanism serves to prevent the freediffusion of indole, which is only released from the α-subunit when thecomplex is in a closed conformation that forms a 25-Å tunnel throughwhich indole diffuses into the β-subunit. Here, indole reacts withE(A-A) in a C—C bond-forming reaction, yielding L-tryptophan as product(FIG. 1B). These allosteric effects are mediated through the rigid-bodymotion of the communication (COMM) domain and a monovalent cation (MVC)binding site within the β-subunit (FIG. 1A), which undergo complexconformational transitions associated with open, partially closed, andfully closed states during the catalytic cycle.

SUMMARY

The disclosure provides a recombinant polypeptide selected from thegroup consisting of: (a) a polypeptide comprising a sequence that is atleast 57% identical to SEQ ID NO:2 and comprises an activating mutationat residues corresponding to residue 144 and 166 of SEQ ID NO:2, whereinthe polypeptide can catalyze the production of tryptophan or anon-canonical amino acid or unnatural amino acid from an indole orindole derivative and L-serine or L-threonine independent of any othertryptophan synthase subunit; (b) a polypeptide comprising a sequencethat is at least 60% identical to SEQ ID NO:2 and having at least oneactivating mutation including a mutation corresponding to residue 292,wherein the polypeptide can catalyze the production of tryptophan or anon-canonical amino acid or unnatural amino acid from an indole orindole derivative and L-serine or L-threonine independent of any othertryptophan synthase subunit. In one embodiment, the mutationcorresponding to residue 292 is a T→S mutation. In yet anotherembodiment, the polypeptide that is at least 60% identical to SEQ IDNO:2 comprises a polypeptide that has a sequence of SEQ ID NO:4 or 6,and wherein SEQ ID NO:4 has a mutation at position 303 and wherein SEQID NO:6 has a mutation at position 292. In a further embodiment, themutations at 303 and 292 are T303S and T292S, respectively. In still afurther embodiment, the polypeptide comprises one or more additionalmutations at residues: (i) 12, 17, 68, 274, and 321 of SEQ ID NO:2; (ii)25, 30, 80, 285 and 332 of SEQ ID NO:4; and (iii) 14, 19, 69, and 274 ofSEQ ID NO:6. In yet a further embodiment, the polypeptide comprises thefollowing residues at the following positions, wherein at least oneposition identified in (i)-(iii) is: substituting an L at position 12,25, or 14, of SEQ ID NO:2, 4, or 6, respectively; and/or substituting Gat position 17, 30, or 19 SEQ ID NO:2, 4, or 6, respectively; and/orsubstituting a V at position 68, 80, or 69 of SEQ ID NO:2, 4, or 6,respectively; and/or substituting S or L at position 274, 285, or 274 ofSEQ ID NO:2, 4, or 6, respectively; and/or substituting S at position292, 303, or 292 of SEQ ID NO:2, 4, or 6, respectively; and/orsubstituting A at position 321 or 332 of SEQ ID NO:2 or 4, respectively.In another embodiment, the polypeptide comprises one or more additionalmutations corresponding to a residue selected from the group consistingof residue 2, 4, 5, 10, 11, 13, 16, 20, 21, 35, 36, 41, 59, 67, 89, 95,123, 127, 144, 146, 150, 166, 178, 180, 181, 182, 220, 233, 267, 272,284, 323, 384 and any combination thereof of SEQ ID NO:2. In anotherembodiment, the polypeptide comprises (i) a sequence of SEQ ID NO:10that include up to 50, 25, 10, or 5 conservative amino acidsubstitutions excluding residues 292 of SEQ ID NO:10; or (ii) a sequencethat is at least 80%, 90%, 95%, 98%, or 100% identical to SEQ ID NO:10and comprises an S at position 292. In another embodiment, thepolypeptide comprises (i) a sequence of SEQ ID NO:12 that include up to50, 25, 10, or 5 conservative amino acid substitutions excludingresidues 12, 17, 68, 274, 292 and 321 of SEQ ID NO:12; or (ii) asequence that is at least 80%, 90%, 95%, 98%, or 100% identical to SEQID NO:12 and comprises the following amino acids residues: L12, G17,V68, S292, S274 and A321. In yet another embodiment, the polypeptidecomprises (i) a sequence of SEQ ID NO:14 that include up to 50, 25, 10,or 5 conservative amino acid substitutions excluding residues 17, 68,95, 274, 292 and 321 of SEQ ID NO:14; or (ii) a sequence that is atleast 80%, 90%, 95%, 98%, or 100% identical to SEQ ID NO:14 andcomprises the following amino acids residues: G17, V68, L95, S274, S292and A321. In another embodiment, the polypeptide comprises (i) asequence of SEQ ID NO:16 that include up to 50, 25, 10, or 5conservative amino acid substitutions excluding residues 17, 68, 274,292, and 321 of SEQ ID NO:16; or (ii) a sequence that is at least 80%,90%, 95%, 98%, or 100% identical to SEQ ID NO:16 and comprises thefollowing amino acids residues: G17, V68, S274, S292 and A321. In stillanother embodiment, the polypeptide comprises (i) a sequence of SEQ IDNO:18 that include up to 50, 25, 10, or 5 conservative amino acidsubstitutions excluding residues 16, 17, 68, 95, 274, 292, 321 and 384of SEQ ID NO:18; or (ii) a sequence that is at least 80%, 90%, 95%, 98%,or 100% identical to SEQ ID NO:18 and comprises the following aminoacids residues: V16, G17, V68, L95, S274, S292, A321 and A384. Inanother embodiment, the polypeptide comprises (i) a sequence of SEQ IDNO:20 that include up to 50, 25, 10, or 5 conservative amino acidsubstitutions excluding residues 144 and 166 of SEQ ID NO:20; or (ii) asequence that is at least 80%, 90%, 95%, 98%, or 100% identical to SEQID NO:20 and comprises the following amino acids residues: T144 andD166. In another embodiment, the polypeptide comprises (i) a sequence ofSEQ ID NO:22 that include up to 50, 25, 10, or 5 conservative amino acidsubstitutions excluding residues 25, 30, 80, 285, 303, and 332 of SEQ IDNO:22; or (ii) a sequence that is at least 80%, 90%, 95%, 98%, or 100%identical to SEQ ID NO:22 and comprises the following amino acidsresidues: L25, G30, V80, S285, S303 and A332. In still anotherembodiment, the polypeptide comprises (i) a sequence of SEQ ID NO:24that include up to 50, 25, 10, or 5 conservative amino acidsubstitutions excluding residues 156 and 178 of SEQ ID NO:24; or (ii) asequence that is at least 80%, 90%, 95%, 98%, or 100% identical to SEQID NO:24 and comprises the following amino acids residues: T156 andD178. In another embodiment, the polypeptide comprises (i) a sequence ofSEQ ID NO:26 that include up to 50, 25, 10, or 5 conservative amino acidsubstitutions excluding residues 292 of SEQ ID NO:26; or (ii) a sequencethat is at least 80%, 90%, 95%, 98%, or 100% identical to SEQ ID NO:26and comprises an S at position 292. In yet another embodiment, thepolypeptide comprises (i) a sequence of SEQ ID NO:28 that include up to50, 25, 10, or 5 conservative amino acid substitutions excludingresidues 19 of SEQ ID NO:28; or (ii) a sequence that is at least 80%,90%, 95%, 98%, or 100% identical to SEQ ID NO:28 and comprises an G atposition 19. In yet another embodiment, the polypeptide comprises (i) asequence of SEQ ID NO:30 that include up to 50, 25, 10, or 5conservative amino acid substitutions excluding residues 19 and 292 ofSEQ ID NO:30; or (ii) a sequence that is at least 80%, 90%, 95%, 98%, or100% identical to SEQ ID NO:30 and comprises the following amino acidsresidues: G19 and S292. In another embodiment, the polypeptide comprises(i) a sequence of SEQ ID NO:32 that include up to 50, 25, 10, or 5conservative amino acid substitutions excluding residues 19 and 69 ofSEQ ID NO:32; or (ii) a sequence that is at least 80%, 90%, 95%, 98%, or100% identical to SEQ ID NO:32 and comprises the following amino acidsresidues: G19 and V69. In still another embodiment, the polypeptidecomprises (i) a sequence of SEQ ID NO:34 that include up to 50, 25, 10,or 5 conservative amino acid substitutions excluding residues 19, 69 and292 of SEQ ID NO:34; or (ii) a sequence that is at least 80%, 90%, 95%,98%, or 100% identical to SEQ ID NO:34 and comprises the following aminoacids residues: G19, V69 and S292. In another embodiment, thepolypeptide comprises (i) a sequence of SEQ ID NO:36 that include up to50, 25, 10, or 5 conservative amino acid substitutions excludingresidues 145 and 167 of SEQ ID NO:36; or (ii) a sequence that is atleast 80%, 90%, 95%, 98%, or 100% identical to SEQ ID NO:36 andcomprises the following amino acids residues: T145 and D167. In yetanother embodiment, the polypeptide comprises (i) a sequence of SEQ IDNO:38 that include up to 50, 25, 10, or 5 conservative amino acidsubstitutions excluding residues 69 and 292 of SEQ ID NO:38; or (ii) asequence that is at least 80%, 90%, 95%, 98%, or 100% identical to SEQID NO:38 and comprises the following amino acids residues: V69 and S292.In another embodiment, the polypeptide comprises (i) a sequence of SEQID NO:40 that include up to 50, 25, 10, or 5 conservative amino acidsubstitutions excluding residues 149 and 171 of SEQ ID NO:40; or (ii) asequence that is at least 80%, 90%, 95%, 98%, or 100% identical to SEQID NO:40 and comprises the following amino acids residues: T149 andD171.

The disclosure also provides an isolated nucleic acid encoding any ofthe foregoing recombinant polypeptides.

The disclosure provides a vector comprising the nucleic acid molecule ofthe disclosure. In one embodiment, the vector is an expression vector.

The disclosure also provides host cells transfected with an isolatednucleic acid or vector of the disclosure.

The disclosure also provides a method for producing tryptophan, anon-canonical amino acid and/or an unnatural amino acid comprisingcontacting an indole or indole analog and L-serine or L-threonine with apolypeptide of the disclosure.

The disclosure also provides a method for producing aβ-methyl-tryptophan or analog thereof, the method comprising: (a)providing L-threonine, an indole or indole analog and a polypeptide(e.g., a mutant TrpB) of the disclosure; and (b) admixing the componentsof (a) in a reaction for a time and under conditions to theβ-methyl-tryptophan or analog thereof. In one embodiment, the indoleanalog is a compound according to Formula I:

wherein X₁-X₇ are independently either a carbon, nitrogen, oxygen, orsulfur; R₁-R₇ are each independently selected from the group consistingof H, —OH, alkyl, aryl, alkoxy, alkenes, alkynes, and substitutions ofthe foregoing, sulfur-containing group, nitrogen-containing groups,oxygen-containing group, or halogen. In a further embodiment, the indoleanalog is selected from the group consisting of:

In another embodiment, the β-methyl-tryptophan or analog thereof isselected from the group consisting of:

wherein X₁-X₇ are independently either a carbon, nitrogen, oxygen, orsulfur; R₂-R₇ are each independently selected from the group consistingof H, —OH, alkyl, aryl, alkoxy, alkenes, alkynes, and substitutions ofthe foregoing, sulfur-containing group, nitrogen-containing groups,oxygen-containing group, or halogen. In a further embodiment, theβ-methyl-tryptophan or analog thereof is selected from the groupconsisting of:

The details of one or more embodiments of the disclosure are set forthin the accompanying drawings and the description below. Other features,objects, and advantages will be apparent from the description anddrawings, and from the claims.

BRIEF DESCRIPTION OF DRAWINGS

FIG. 1A shows the last two steps in the biosynthesis of L-Trp catalyzedby the multi-enzyme complex tryptophan synthase. IGP is cleaved into G3Pand indole by TrpA. The latter serves as nucleophile in theTrpB-catalyzed replacement reaction of the L-Ser hydroxyl to give L-Trp.G3P and water are released as side products of the overall reaction.

FIG. 1B shows a depiction of the mechanism of the β-replacement reactionin tryptophan synthase divided into α, β-elimination of L-Ser (stage I)and nucleophilic addition of indole (stage II). The wavelengths beneatheach intermediate belong to maximum absorbances observed in TrpB from E.coli and S. typhimurium.

FIG. 2 shows a multiple sequence alignment of Pf (SEQ ID NO:2), Af (SEQID NO:4), Tm (SEQ ID NO:6) and Ec (SEQ ID NO:8) TrpB homologs. Themutated residues in PfTrpB^(0B2) are shown above the first line. Symbolsunder sequences: (*) identify identical residues, (:) report forresidues of equal nature, and (.) recognize roughly similar residues.

FIG. 3 shows an SDS-PAGE of PfTrpA, PfTrpB, and PfTrpS. 1, PfTrpA, 2,PfTrpB; 3-5, aliquots from 1.5-mL fractions from PfTrpA pull-down usingHis-tagged PfTrpB; 4-20% gradient, SDS-PAGE. MW from ColorPlusPrestained Protein Ladder (New England Biosystems) is on right.

FIG. 4A-B shows substrate profile of native and engineered TrpB enzymes.(A) Indole analogs that have been reported to react with StTrpS weretested for reactivity with the PfTrpB, PfTrpS, and PfTrpB^(0B2) enzymes.The nucleophilic atom is indicated with a gray circle. (B) Relativeactivities of enzyme complex PfTrpS (black) and PfTrpB^(0B2) (gray)compared with PfTrpB. Reactions performed in duplicate with 20 mM ofeach substrate and varying enzyme concentrations to ensure incompleteconversion after 1 h. Products were later confirmed in scaled-upreactions using PfTrpB^(0B2).

FIG. 5A-C shows structural transitions upon ligand binding in PfTrpB.(A) Superimposition of PfTrpB-E(Ain) and PfTrpB-E(Aex1), respectively.Overlay shows the 2.1-Å displacement of the COMM domain upon E(Aex1)formation. This closure moves the side chain of Glu104 by 3.7 Å, towardits catalytic orientation (dashes). (B) Structure of Ser-bound PfTrpBwith a Fo-Fc map of E(Aex1) contoured at 3.0 G. (C) Structure ofL-tryptophan-bound PfTrpB with Fo-Fc map of Trp ligand contoured at 3.0σ.

FIG. 6A-D shows distribution of PfTrpB^(0B2) mutations and interactionnetworks altered by mutational reactivation. (A) PfTrpB residues within5 Å of PfTrpA and the COMM domain are depicted. (B) A hydrogen bondbetween D300 and E(Aex1) in the Ser-bound structure (dashes) is formedtransiently during the catalytic cycle. When this H-bond is severed,D300 may interact with T292 (no ligands or Trp-bound are depicted). Thiscomplex network is centered on a monovalent cation cofactor, shown hereas Na+, which is known to mediate allosteric interactions between the α-and β-subunits. (C) Residues F274 and H275 undergo a rotameric shiftupon substrate or product binding into an open state. (D) In the closedstate (no ligands bound), H275 blocks access to the active site.

FIG. 7 shows structural alignment of PfTrpB (PDB entry 5DVZ) and EcTrpB(PDB entry 2DH5). The residues mutated in PfTrpB^(0B2) are shown insticks. To facilitate view, a zoomed detail of the region of themutations is shown together with a label indicating the mutations.

FIG. 8 shows the k_(cat) values of TmTrpS and all TmTrpB studiedvariants. The mutation is labeled below each bar.

FIG. 9 shows UV-vis spectra of TmTrpS and all TmTrpB studied variants.The mutation is labeled below each graph. Spectra with the holo-proteinare represented. To facilitate view, the registered spectra afteraddition of L-serine are represented when they resemble the E(A-A)characteristic spectrum and either the E(Aex₁) or a spectrum not fullyequivalent to the E(A-A).

Like reference symbols in the various drawings indicate like elements.

DETAILED DESCRIPTION

Before describing the invention in detail, it is to be understood thatthis invention is not limited to particular compositions or biologicalsystems, which can, of course, vary. It is also to be understood thatthe terminology used herein is for the purpose of describing particularembodiments only, and is not intended to be limiting.

As used in this specification and the appended claims, the singularforms “a,” “an,” and “the” include plural referents unless the contentclearly dictates otherwise.

Unless defined otherwise, all technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art to which the invention pertains. Although any methods andmaterials similar or equivalent to those described herein can be used inthe practice for testing of the invention(s), specific examples ofappropriate materials and methods are described herein.

Also, the use of “or” means “and/or” unless stated otherwise. Similarly,“comprise,” “comprises,” “comprising” “include,” “includes,” and“including” are interchangeable and not intended to be limiting.

It is to be further understood that where descriptions of variousembodiments use the term “comprising,” those skilled in the art wouldunderstand that in some specific instances, an embodiment can bealternatively described using language “consisting essentially of” or“consisting of.”

Any publications discussed above and throughout the text are providedsolely for their disclosure prior to the filing date of the presentapplication. Nothing herein is to be construed as an admission that theinventors are not entitled to antedate such disclosure by virtue ofprior disclosure.

TrpS is a naturally promiscuous enzyme complex: the model system from S.typhimurium catalyzes its β-substitution reaction with most haloindoles,methylindoles, and aminoindoles, along with an assortment of nonindolenucleophiles for C—S, C—N, and C—C bond formation. Such noncanonicalamino acids (NCAAs) have diverse applications in chemical biology, serveas intermediates in the synthesis of natural products, and areprivileged scaffolds for the development of pharmaceuticals. Despite itsnatural ability to produce these desirable compounds, TrpS has enjoyedonly limited application. Optimized methods are restricted by lowsubstrate concentrations and yields typically below 50%. To produceNCAAs, researchers have used the S. typhimurium TrpS complex (StTrpS),which suffers from poor thermostability and low tolerance to organicsolvents. Although only the reactivity of the β-subunit, coupling ofL-serine and indole, is necessary and desirable for syntheticapplications, using TrpB as an isolated enzyme has not been feasible.Outside of its native complex, TrpB loses up to 95% of its nativeactivity and is subject to inactivation.

Tryptophan synthase is typically found as a bi-enzyme complex linearlyarranged. The smaller α-subunit (27 kDa) adopts a TIM β/α barrel. ThePLP-dependent β-subunit (43 kDa) is of a fold type II conformation andfeatures a monovalent cation-binding site adjacent to its catalyticcenter. The active sites of the subunits are interconnected by asubstrate tunnel for efficient channeling of the common metabolite,indole. A great degree of allosteric regulation by an intricate networkof interactions is necessary to synchronize the catalytic activities inthe spatially separated active sites of the tryptophan synthase complex.A variety of analytical tools have been sought out to gain a moredetailed mechanical and chemical understanding of the allostericregulation mechanisms involved in catalysis, including biochemicalsolution experiments, mutational studies, and X-ray crystallography. Themost essential feature allowing for the high enzymatic efficiency oftryptophan synthase is the direct channeling of the common intermediate,indole, through the hydrophobic 25-Å long substrate tunnelinterconnecting the active sites of the subunits.

The interest in non-canonical amino acids (NCAA) has been exponentiallygrowing ever since the possibility of their site-specific introductioninto enzymes both in vivo and in vitro through nonsense codonsuppression. A large and diverse library of unnatural amino acids (UAAs)has been established to address unresolved questions in proteinstructure and function with unreached precision. The applications arenumerous, including incorporation of biophysical probes, such asfluorescent tags and spin labels, production of “caged” proteins withphotoreactive side chains, assessing protein stability, and improvingnatural enzyme activity.

Furthermore, compounds of peptidic structure are often found in natureand employed in drugs by the pharmaceutical industry. However, chemicalsynthesis of these substances can be challenging. As part of thegreen-chemistry movement the enzymatic synthesis of non-canonicalpeptidic compounds has gained in importance. In addition to the mildconditions and nontoxic reagents, enzymatic reactions often occur withhigh enantiomeric purity and remarkable rate acceleration.

Tryptophan synthase has also been extensively employed for the enzymaticsynthesis of a variety of tryptophan analogues, including methylated,halogenated, and aminated L-tryptophans, dihydroisotryptophan, andselenatryptophan. The common basic approach of the aforementioned casesconsists of creating batch reactions of indole analogues and L-Sercatalyzed by native tryptophan synthases.

Tryptophan synthase comprises a polymeric polypeptide of two alpha andtwo beta subunits referred to a TrpA (tryptophan-α) and TrpB(tryptophan-β) that form an α-ββ-α complex. The α and ρ subunits havemolecular masses of 27 and 43 kDa, respectively. The α subunit has a TIMbarrel conformation. The β subunit has a fold type II conformation and abinding site adjacent to the active site for monovalent cations. Theirassembly into a complex leads to structural changes in both subunitsresulting in reciprocal activation. There are two main mechanisms forintersubunit communication. First, the COMM domain of the β-subunit andthe α-loop2 of the α-subunit interact. Additionally, there areinteractions between the αGly181 and βSer178 residues. The active sitesare regulated allosterically and undergo transitions between open,inactive, and closed, active, states.

As used herein an “indole analog” refers to any number of knownderivatives of indole as set forth in Formula I:

wherein X₁-X₇ are independently either a carbon, nitrogen, oxygen, orsulfur; R₁-R₇ are each independently selected from the group consistingof H, —OH, alkyl, aryl, alkoxy, alkenes, alkynes, and substitutions ofthe foregoing, sulfur-containing group (e.g., thioalkoxy),nitrogen-containing groups (e.g., amide, amino, nitro, azide, andcyano), oxygen-containing group (e.g., ketone, aldehyde, ester, ether,carboxylic acid, and acyl halide), or halogen (e.g., Br, F, iodine). Inone embodiment, the indole analog is selected from the group consistingof:

As used herein a “mutant TrpB” or “engineered TrpB” refers to theβ-subunit of tryptophan synthase (TrpS) that has been recombinantlymodified to differ from the wild-type sequence. A mutant TrpB typicallyhas a desired substrates specificity, turnover number, productproduction, stability etc. that differ from a wild-type enzyme orsubunit. A mutant TrpB can be derived from a number of homologs ofdiverse origin, wherein the mutant TrpB differs from a wild-type ofparental polypeptide by one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10,15, 20, 25, 30 or more, up to about 50) mutations and wherein the mutantTrpB can generate NCAA or UAA amino acids from an indole analog and aserine or threonine substrate and/or wherein the mutant TrpB functionsindependent of the TrpA subunit.

A “mutant”, “variant” or “modified” protein, enzyme, polynucleotide,gene, or cell, means a protein, enzyme, polynucleotide, gene, or cell,that has been altered or derived, or is in some way different orchanged, from a parent protein, enzyme, polynucleotide, gene, or cell. Amutant or modified protein or enzyme is usually, although notnecessarily, expressed from a mutant polynucleotide or gene.

A “mutation” means any process or mechanism resulting in a mutantprotein, enzyme, polynucleotide, gene, or cell. This includes anymutation in which a protein, enzyme, polynucleotide, or gene sequence isaltered, and any detectable change in a cell arising from such amutation. Typically, a mutation occurs in a polynucleotide or genesequence, by point mutations, deletions, or insertions of single ormultiple nucleotide residues. A mutation includes polynucleotidealterations arising within a protein-encoding region of a gene as wellas alterations in regions outside of a protein-encoding sequence, suchas, but not limited to, regulatory or promoter sequences. A mutation ina gene can be “silent”, i.e., not reflected in an amino acid alterationupon expression, leading to a “sequence-conservative” variant of thegene. This generally arises when one amino acid corresponds to more thanone codon.

Modified amino acids are amino acids that are chemically modified.Non-limiting examples of a modified amino acid include a glycosylatedamino acid, a sulfated amino acid, a prenylated (e.g., farnesylated,geranylgeranylated) amino acid, an acetylated amino acid, an acylatedamino acid, a pegylated amino acid, a biotinylated amino acid, acarboxylated amino acid, a phosphorylated amino acid, and the like.References adequate to guide one of skill in the modification of aminoacids are replete throughout the literature. Example protocols are foundin Walker (1998) Protein Protocols on CD-ROM (Humana Press, Towata,N.J.).

A “parent” protein, enzyme, polynucleotide, gene, or cell, is anyprotein, enzyme, polynucleotide, gene, or cell, from which any otherprotein, enzyme, polynucleotide, gene, or cell, is derived or made,using any methods, tools or techniques, and whether or not the parent isitself native or mutant. A parent polynucleotide or gene encodes for aparent protein or enzyme.

A “parental polypeptide” refers to a polypeptide used to generate arecombinant or mutant polypeptide. The term “parental polypeptide”describes a polypeptide that occurs in nature, i.e. a “wild-type” cellthat has not been genetically modified. The term “parental polypeptide”also describes a polypeptide that serves as the “parent” for furtherengineering. For example, a wild-type polypeptide can be mutant to havea first mutation or set of mutations that can provide a desiredbiological activity or be “silent mutations”. This first mutantpolypeptide can then act as a parental polypeptide in the generation ofsecond mutation or set of mutations that can provide a desiredbiological activity or be silent mutations.

The term “polynucleotide,” “nucleic acid” or “recombinant nucleic acid”refers to polynucleotides such as deoxyribonucleic acid (DNA), and,where appropriate, ribonucleic acid (RNA).

A “protein” or “polypeptide”, which terms are used interchangeablyherein, comprises one or more chains of chemical building blocks calledamino acids that are linked together by chemical bonds called peptidebonds. A protein or polypeptide can function as an enzyme. An “enzyme”means any substance, composed wholly or largely of protein, thatcatalyzes or promotes, more or less specifically, one or more chemicalor biochemical reactions.

As used herein “TrpB” refers to a diverse set of homologs of theβ-subunit of tryptophan synthase. A wild-type TrpB can be used as aparental polypeptide for mutation. For example, the TrpB from Pyroccousfuriosus (PfTrpB) is used as a reference sequence in the disclosure andcomprises or consists of the sequence as set forth in SEQ ID NO:2.Homologs of PfTrpB are known and include, for example, TrpB fromArchaeoglobus fulgidus (Af), which has 72% sequence identity to PfTrpB,and TrpB from Escherichia coli (Ec), which has 57% sequence identity toPfTrpB. Accordingly, wild-type TrpB sequences having at least 57%sequence identity to SEQ ID NO:2 can be used as a parental polypeptidefor mutations to form mutant TrpB. The disclosure demonstrates that adiverse set of TrpB homologs based on a phylogenetic analysis of TrpB,including Archaeoglobus fulgidus (AfTrpB, 72% sequence identity),Thermotoga maritima (TmTrpB, 64%), and Escherichia coli (EcTrpB, 57%)are useful in obtaining desirable mutant TrpBs. A multiple-sequencealignment with PfTrpB is shown in FIG. 2.

The engineered/mutant tryptophan beta-subunits (TrpBs) describedthroughout the present disclosure were acquired by accumulating pointmutations in directed evolution experiments from a parental polypeptide.An alternative method for making libraries for directed evolution toobtain modified TrpBs with new or altered properties is recombination,or chimeragenesis, in which portions of homologous TrpBs are swapped toform functional chimeras. Therefore, the amino acid mutations made inthis way are less disruptive, on average, than random mutations. Astructure-based algorithm, such as SCHEMA, identifies fragments ofproteins that can be recombined to minimize disruptive interactions thatwould prevent the protein from folding into its active form.

Provided herein are variants of TrpB that catalyze the synthesis ofNCAAs and UAAs. The reaction uses indole analogs and L-serine orL-threonine or analogs thereof.

The term “total turnover number” (TTN) is the total number of substratemolecules converted to product (or turned over) by an enzyme over itslifetime or during a specified time period. TTN is an important figureof merit for a catalyst because it allows for the calculation of thetotal amount of product that can be made from a given quantity ofcatalyst.

The modified TrpB subunits used as catalyst can function at ambienttemperature or higher (e.g., from 20° C. to 95° C., typically about 75°C.) and ambient pressure.

The mutant TrpBs of the disclosure have enormous potential forapplications in drug discovery, chemical synthesis, pharmaceuticalpreparations, and biotechnology. However, tailoring TrpBs to acceptnonnatural substrates, as required by many applications, is difficult inthis catalytic system, which involves multiple subunits havingallosteric interactions. Compared to their natural counterparts,engineered/mutant TrpBs of the disclosure have improved catalytic andcoupling efficiencies.

The phrase “TrpB activity” refers to the biological activity of TrpB ormutants thereof. For example, TrpB activity includes the ability of theTrpB polypeptide to produce NCAAs or UAAs from an indole or derivativethereof and L-serine or L-threonine.

The term “substrate” or “suitable substrate” means any substance orcompound that is converted or meant to be converted into anothercompound by the action of an enzyme catalyst. The term includes indoleand indole derivatives as well as serine or threonine and derivativesthereof.

As will be described in more detail below, the disclosure is based, atleast in part, on the generation and expression of novel enzymes thatcatalyze the conversion of indole or indole derivatives and serine orthreonine to NCAAs or UAAs. In one embodiment, polypeptides that havebeen engineered to convert an indole and serine or threonine to an NCAAor UAA are provided.

While the TrpB mutants will be described in more detail below, it isunderstood that polypeptides of the disclosure may contain one or moremodified amino acids. Amino acid(s) are modified, for example,co-translationally or post-translationally during recombinant production(e.g., N-linked glycosylation at N—X—S/T motifs during expression inmammalian cells) or modified by synthetic means.

The disclosure demonstrates the engineering of TrpB through directedevolution to provide a β-subunit that has biological activityindependent of TrpA and which can produce tryptophan and/or NCAAs orUAAs from suitable substrates. For example, the evolution of TrpB intoTrpB mutants shows that members of the TrpB family can be evolved bypoint mutations and screening for function on various substrates andvarious products production.

Referring to the sequence comparison of various TrpB subunits in FIG. 2,SEQ ID NO:2 includes the amino acid sequence of TrpB isolated fromPyroccocus furiosus designated PfTrpB. SEQ ID NO:4 provides the aminoacid sequence of wild-type TrpB from Archaeoglobus fulgidus. Thiswild-type TrpB designated AfTrpB shares 72% amino acid sequence identityto PfTrpB (SEQ ID NO:2). SEQ ID NO:6 includes the amino acid sequence ofwild-type TrpB from Thermotoga maritima. This wild-type TrpB isdesignated TmTrpB and shares 64% amino acid sequence identity to PfTrpB(SEQ ID NO:2). SEQ ID NO:8 includes the amino acid sequence of wild-typeTrpB from Escherichia coli. This wild-type TrpB is designated EcTrpB andshares 57% amino acid sequence identity to PfTrpB (SEQ ID NO:2).

The TrpBs set forth in SEQ ID NOs:2, 4, 6, and 8 are closely related toone another and show a high degree of sequence identity and activity.The sequences can be aligned and conserved amino acids identified basedupon the alignment. The alignment provided in FIG. 2 identifies“equivalent positions” in the sequences. An equivalent position denotesa position which, on the basis of the alignment of the sequence of theparent TrpB in question with the “reference” TrpB amino acid sequence inquestion (e.g. SEQ ID NO: 2) so as to achieve juxtapositioning of aminoacid residues which are common to both, corresponds most closely to aparticular position in the reference sequence in question. This processcan cause gaps or insertions to appear in the sequences. In thealignment of FIG. 2, equivalent positions are shown lined up verticallywith one another. For example, position 47 in SEQ ID NO: 2 is equivalentto position 60 in SEQ ID NO: 4 and position 49 in SEQ ID NO: 6 andposition 53 in SEQ ID NO:8.

Provided herein are engineered mutant TrpB polypeptides capable ofproducing NCAAs and UAAs. Protein engineering of TrpBs from othersources can be expected to lead to a similar result using the basicalignment and mutation tools described herein. It is well known in theart that amino acid substitutions having a particular effect (e.g. thatconfer activity toward a new substrate) can have the same effect inclosely related proteins. For example, the alignment of these fourhomologs illustrates the high degree of sequence similarity among thefour TrpBs. Moreover, it will be readily apparent based upon the“mutation” row, which exemplary mutations can be and have been made. Ithas been shown on multiple occasions that amino acid substitutions atequivalent positions in these enzymes have equivalent effects onfunction. For example, the substitution of M144T and N166D in PfTrpBincreases the k_(cat) by at least 2-fold. The same substitution of theequivalent position in AfTrpB, TmTrpB, and EcTrpB, which is M156T/N178D,M145T/N167D, and M149T/N171D (respectively), has the same effect.Additionally, these TrpB polypeptides can be subjected to rounds ofdirected evolution using the techniques and screens described herein toobtain and/or increase substrate specificity and product generation.

Accordingly, in one embodiment, a mutant TrpB polypeptide is providedthat comprises at least 57% identity to SEQ ID NO:2 and comprisesactivating mutations at position 144 and 166. In one embodiment, theactivating mutations are an M144T and N166D mutation. In anotherembodiment, the mutant TrpB comprises 50, 25, 10, 5 or fewerconservative substitutions to SEQ ID NO:8 and a M149T and N171Dmutation. In another embodiment, the mutant TrpB comprises 50, 25, 10, 5or fewer conservative substitutions to SEQ ID NO:6 and a M145T and N167Dmutation. In another embodiment, the mutant TrpB comprises 50, 25, 10, 5or fewer conservative substitutions to SEQ ID NO:4 and a M156T and N178Dmutation.

In yet another embodiment, a mutant TrpB polypeptide is provided thatcomprises SEQ ID NO:2 and has at least 50, 25, 10, 5 or fewerconservative substitutions and activating mutations at positions 12, 17,68, 274, 292 and 321. In a further embodiment, the activating mutationsare P12L, E17G, I68V, F274S, T292S and T321A.

In yet another embodiment, a mutant TrpB polypeptide is provided thatcomprises SEQ ID NO:4 and has at least 50, 25, 10, 5 or fewerconservative substitutions and activating mutations at positions 25, 30,80, 285, 303 and 332. In a further embodiment, the activating mutationsare P25L, E30G, 180V, F285S, T303S and T332A.

In yet another embodiment, a mutant TrpB polypeptide is provided thatcomprises SEQ ID NO:6 and has at least 50, 25, 10, 5 or fewerconservative substitutions and activating mutations at positions 19, 68and 292. In a further embodiment, the activating mutations are P19L,I68V, and T292S.

In one embodiment, a mutant TrpB polypeptide is provided that comprisesat least 60% sequence identity to SEQ ID NO:2 and comprises at least amutation at residue 292 of SEQ ID NO:2 or a related position in ahomolog of SEQ ID NO:2 (e.g., residue 303 of SEQ ID NO:4, or residue 292of SEQ ID NO:6). In one embodiment, the residue is replaced with aSerine residue. In a particular embodiment, the mutant TrpB comprises atleast 65%, 70%, 75%, 80%, 85%, 88%, 90%, 92%, 95%, 98% or at least 99%identity to SEQ ID NO:2 and comprises a mutation at position 292 or arelated position in a homolog of SEQ ID NO:2. In still a furtherembodiment, the TrpB polypeptide can comprise one or more additionalmutations at residues: (a) 12, 17, 68, 274, and 321 of SEQ ID NO:2; (b)25, 30, 80, 285, and 332 of SEQ ID NO:4; (c) 14, 19, 69, 274, and 321 ofSEQ ID NO:6; and (d) 18, 23, 73, 279, and 326 of SEQ ID NO:8. In still afurther embodiment, the amino acid sequence of the TrpB mutant includesthe following residues at the following positions, wherein at least oneposition identified in (a)-(d) a specific mutation is provided. In oneembodiment, the specific mutation is substituting an L at position 12,25, 14, or 18 of SEQ ID NO:2, 4, 6, or 8, respectively; and/orsubstituting G at position 17, 30, 19, or 23 of SEQ ID NO:2, 4, 6, or 8,respectively; and/or substituting a V at position 68 68, 80, 69, or 73of SEQ ID NO:2, 4, 6, or 8, respectively; and/or substituting S or L atposition 274, 285, 274, or 279 of SEQ ID NO:2, 4, 6, or 8, respectively;and/or substituting S at position 292, 303, or 292 of SEQ ID NO:2, 4, or6, respectively; and/or A at position 321, 332, or 326 of SEQ ID NO:2,4, or 8, respectively. In still a further embodiment, one or moreadditional mutations may be present. The one or more additionalmutations can be at residues selected from the group consisting ofresidue 2, 4, 5, 10, 11, 13, 16, 20, 21, 35, 36, 41, 59, 67, 89, 95,123, 127, 144, 146, 150, 166, 178, 180, 181, 182, 220, 233, 267, 272,284, 323, 384 of SEQ ID NO:2.

In yet other various embodiments, mutant TrpB polypeptides are provided.The mutant TrpB polypeptides include up to 50, 25, 10, or 5 conservativeamino acid substitutions excluding residues: (a) 12, 17, 68, 274, 292and 321 of SEQ ID NO:2; (b) 25, 30, 80, 285, 303, and 332 of SEQ IDNO:4; (c) 14, 19, 69, 274, 292 and 321 of SEQ ID NO:6; and (d) 18, 23,73, 279, 297 and 326 of SEQ ID NO:8. The amino acid sequence includesthe following residues at the following positions, wherein at at leastone position identified in (a)-(d) a specific mutation is provided. Inone embodiment, the specific mutation is substituting an L at position12, 25, 14, or 18 of SEQ ID NO:2, 4, 6, or 8, respectively; and/orsubstituting G at position 17, 30, 19 or 23 of SEQ ID NO:2, 4, 6, or 8,respectively; and/or substituting a V at position 68 68, 80, 69 or 73 ofSEQ ID NO:2, 4, 6, or 8, respectively; and/or substituting S or L atposition 274, 285, 274, or 279 of SEQ ID NO:2, 4, 6, or 8, respectively;and/or substituting S at position 292, 303, 292, or 297 of SEQ ID NO:2,4, 6, or 8, respectively (note that for SEQ ID NO:8 although referred toin this paragraph as a specific mutation, the residue at position 297 isnot mutated); and/or A at position 321, 332, 321 or 326 of SEQ ID NO:2,4, 6, or 8, respectively (note that for SEQ ID NO:6 although referred toin this paragraph as a specific mutation, the residue at position 321 isnot mutated). In still a further embodiment, one or more additionalmutations may be present. The one or more additional mutations are atresidues selected from the group consisting of residue 2, 4, 5, 10, 11,13, 16, 20, 21, 35, 36, 41, 59, 67, 89, 95, 123, 127, 144, 146, 150,166, 178, 180, 181, 182, 220, 233, 267, 272, 284, 323, 384 of SEQ IDNO:2.

In another embodiment, the disclosure provides a polypeptide thatcomprises at least 57% identity to SEQ ID NO:2 and has at least onemutation at (a) a residue selected from the group consisting of 12, 17,68, 274, 292, 321 and any combination thereof of SEQ ID NO:2; (b) aresidue selected from the group consisting of 25, 30, 80, 285, 303, 332,and any combination thereof of SEQ ID NO:4; (c) a residue selected fromthe group consisting of 14, 19, 69, 274, or 292 and any combinationthereof of SEQ ID NO:6; and (d) a residue selected from the groupconsisting of 18, 23, 73, 279, or 326 and any combination thereof of SEQID NO:8. In a further embodiment, at least one position identified in(a)-(d) includes a substitution of L at position 12, 25, 14, or 18 ofSEQ ID NO:2, 4, 6, or 8, respectively; and/or substituting G at position17, 30, 19 or 23 of SEQ ID NO:2, 4, 6, or 8, respectively; and/orsubstituting a V at position 68 68, 80, 69 or 73 of SEQ ID NO:2, 4, 6,or 8, respectively; and/or substituting S or L at position 274, 285,274, or 279 of SEQ ID NO:2, 4, 6, or 8, respectively; and/orsubstituting S at position 292, 303, or 292 of SEQ ID NO:2, 4, or 6,respectively; and/or A at position 321, 332, or 326 of SEQ ID NO:2, 4,or 8, respectively.

In yet another embodiment, a mutant TrpB polypeptide comprises asequence of SEQ ID NO:10 that include up to 50, 25, 10, or 5conservative amino acid substitutions excluding residues 292 of SEQ IDNO:10. In still another embodiment, a mutant TrpB polypeptide isprovided that comprises a sequence that is at least 80%, 90%, 95%, 98%,or 100% identical to SEQ ID NO:10 and comprises an S at position 292.

In yet another embodiment, a mutant TrpB polypeptide comprises asequence of SEQ ID NO:12 that include up to 50, 25, 10, or 5conservative amino acid substitutions excluding residues 12, 17, 68,274, 292 and 321 of SEQ ID NO:12. In still another embodiment, a mutantTrpB polypeptide is provided that comprises a sequence that is at least80%, 90%, 95%, 98%, or 100% identical to SEQ ID NO:12 and comprises thefollowing amino acids residues: L12, G17, V68, S292, S274, and A321.

In yet another embodiment, a mutant TrpB polypeptide comprises asequence of SEQ ID NO:14 that include up to 50, 25, 10, or 5conservative amino acid substitutions excluding residues 17, 68, 95,274, 292, and 321 of SEQ ID NO:14. In still another embodiment, a mutantTrpB polypeptide is provided that comprises a sequence that is at least80%, 90%, 95%, 98%, or 100% identical to SEQ ID NO:14 and comprises thefollowing amino acids residues: G17, V68, L95, S274, S292, and A321.

In yet another embodiment, a mutant TrpB polypeptide comprises asequence of SEQ ID NO:16 that include up to 50, 25, 10, or 5conservative amino acid substitutions excluding residues 17, 68, 274,292, and 321 of SEQ ID NO:16. In still another embodiment, a mutant TrpBpolypeptide is provided that comprises a sequence that is at least 80%,90%, 95%, 98%, or 100% identical to SEQ ID NO:16 and comprises thefollowing amino acids residues: G17, V68, S274, S292, and A321.

In yet another embodiment, a mutant TrpB polypeptide comprises asequence of SEQ ID NO:18 that include up to 50, 25, 10, or 5conservative amino acid substitutions excluding residues 16, 17, 68, 95,274, 292, 321, and 384 of SEQ ID NO:18. In still another embodiment, amutant TrpB polypeptide is provided that comprises a sequence that is atleast 80%, 90%, 95%, 98%, or 100% identical to SEQ ID NO:18 andcomprises the following amino acids residues: V16, G17, V68, L95, S274,S292, A321, and A384.

In yet another embodiment, a mutant TrpB polypeptide comprises asequence of SEQ ID NO:20 that include up to 50, 25, 10, or 5conservative amino acid substitutions excluding residues 144 and 166 ofSEQ ID NO:20. In still another embodiment, a mutant TrpB polypeptide isprovided that comprises a sequence that is at least 80%, 90%, 95%, 98%,or 100% identical to SEQ ID NO:20 and comprises the following aminoacids residues: T144 and D166.

In yet another embodiment, a mutant TrpB polypeptide comprises asequence of SEQ ID NO:22 that include up to 50, 25, 10, or 5conservative amino acid substitutions excluding residues 25, 30, 80,285, 303, and 332 of SEQ ID NO:22. In still another embodiment, a mutantTrpB polypeptide is provided that comprises a sequence that is at least80%, 90%, 95%, 98%, or 100% identical to SEQ ID NO:22 and comprises thefollowing amino acids residues: L25, G30, V80, S285, S303, and A332.

In yet another embodiment, a mutant TrpB polypeptide comprises asequence of SEQ ID NO:24 that include up to 50, 25, 10, or 5conservative amino acid substitutions excluding residues 156 and 178 ofSEQ ID NO:24. In still another embodiment, a mutant TrpB polypeptide isprovided that comprises a sequence that is at least 80%, 90%, 95%, 98%,or 100% identical to SEQ ID NO:24 and comprises the following aminoacids residues: T156 and D178.

In yet another embodiment, a mutant TrpB polypeptide comprises asequence of SEQ ID NO:26 that include up to 50, 25, 10, or 5conservative amino acid substitutions excluding residues 292 of SEQ IDNO:26. In still another embodiment, a mutant TrpB polypeptide isprovided that comprises a sequence that is at least 80%, 90%, 95%, 98%,or 100% identical to SEQ ID NO:26 and comprises an S at position 292.

In yet another embodiment, a mutant TrpB polypeptide comprises asequence of SEQ ID NO:28 that include up to 50, 25, 10, or 5conservative amino acid substitutions excluding residues 19 of SEQ IDNO:28. In still another embodiment, a mutant TrpB polypeptide isprovided that comprises a sequence that is at least 80%, 90%, 95%, 98%,or 100% identical to SEQ ID NO:28 and comprises an G at position 19.

In yet another embodiment, a mutant TrpB polypeptide comprises asequence of SEQ ID NO:30 that include up to 50, 25, 10, or 5conservative amino acid substitutions excluding residues 19 and 292 ofSEQ ID NO:30. In still another embodiment, a mutant TrpB polypeptide isprovided that comprises a sequence that is at least 80%, 90%, 95%, 98%,or 100% identical to SEQ ID NO:30 and comprises the following aminoacids residues: G19 and S292.

In yet another embodiment, a mutant TrpB polypeptide comprises asequence of SEQ ID NO:32 that include up to 50, 25, 10, or 5conservative amino acid substitutions excluding residues 19 and 69 ofSEQ ID NO:32. In still another embodiment, a mutant TrpB polypeptide isprovided that comprises a sequence that is at least 80%, 90%, 95%, 98%,or 100% identical to SEQ ID NO:32 and comprises the following aminoacids residues: G19 and V69.

In yet another embodiment, a mutant TrpB polypeptide comprises asequence of SEQ ID NO:34 that include up to 50, 25, 10, or 5conservative amino acid substitutions excluding residues 19, 69 and 292of SEQ ID NO:34. In still another embodiment, a mutant TrpB polypeptideis provided that comprises a sequence that is at least 80%, 90%, 95%,98%, or 100% identical to SEQ ID NO:34 and comprises the following aminoacids residues: G19, V69, and S292.

In yet another embodiment, a mutant TrpB polypeptide comprises asequence of SEQ ID NO:36 that include up to 50, 25, 10, or 5conservative amino acid substitutions excluding residues 145 and 167 ofSEQ ID NO:36. In still another embodiment, a mutant TrpB polypeptide isprovided that comprises a sequence that is at least 80%, 90%, 95%, 98%,or 100% identical to SEQ ID NO:36 and comprises the following aminoacids residues: T145 and D167.

In yet another embodiment, a mutant TrpB polypeptide comprises asequence of SEQ ID NO:38 that include up to 50, 25, 10, or 5conservative amino acid substitutions excluding residues 69 and 292 ofSEQ ID NO:38. In still another embodiment, a mutant TrpB polypeptide isprovided that comprises a sequence that is at least 80%, 90%, 95%, 98%,or 100% identical to SEQ ID NO:38 and comprises the following aminoacids residues: V69 and S292.

In yet another embodiment, a mutant TrpB polypeptide comprises asequence of SEQ ID NO:40 that include up to 50, 25, 10, or 5conservative amino acid substitutions excluding residues 149 and 171 ofSEQ ID NO:40. In still another embodiment, a mutant TrpB polypeptide isprovided that comprises a sequence that is at least 80%, 90%, 95%, 98%,or 100% identical to SEQ ID NO:40 and comprises the following aminoacids residues: T149 and D171.

“Conservative amino acid substitution” or, simply, “conservativevariations” of a particular sequence refers to the replacement of oneamino acid, or series of amino acids, with essentially identical aminoacid sequences. One of skill will recognize that individualsubstitutions, deletions, or additions which alter, add, or delete asingle amino acid or a percentage of amino acids in an encoded sequenceresult in “conservative variations” where the alterations result in thedeletion of an amino acid, addition of an amino acid, or substitution ofan amino acid with a chemically similar amino acid.

Conservative substitution tables providing functionally similar aminoacids are well known in the art. For example, one conservativesubstitution group includes Alanine (A), Serine (S), and Threonine (T).Another conservative substitution group includes Aspartic acid (D) andGlutamic acid (E). Another conservative substitution group includesAsparagine (N) and Glutamine (Q). Yet another conservative substitutiongroup includes Arginine (R) and Lysine (K). Another conservativesubstitution group includes Isoleucine, (I) Leucine (L), Methionine (M),and Valine (V). Another conservative substitution group includesPhenylalanine (F), Tyrosine (Y), and Tryptophan (W).

Thus, “conservative amino acid substitutions” of a listed polypeptidesequence (e.g., SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24,26, 28, 30, 32, 34, 36, 28 or 40) include substitutions of a percentage,typically less than 10%, of the amino acids of the polypeptide sequence,with a conservatively selected amino acid of the same conservativesubstitution group. Accordingly, a conservatively substituted variationof a polypeptide of the disclosure can contain 100, 75, 50, 25, or 10substitutions with a conservatively substituted variation of the sameconservative substitution group.

It is understood that the addition of sequences which do not alter theencoded activity of a nucleic acid molecule, such as the addition of anon-functional or non-coding sequence, is a conservative variation ofthe basic nucleic acid.

The “activity” of an enzyme is a measure of its ability to catalyze areaction, i.e., to “function”, and may be expressed as the rate at whichthe product of the reaction is produced. For example, enzyme activitycan be represented as the amount of product produced per unit of time orper unit of enzyme (e.g., concentration or weight), or in terms ofaffinity or dissociation constants. As used interchangeably herein a“TrpB mutant activity”, “biological activity of TrpB mutant” or“functional activity of TrpB mutant”, refers to an activity exerted by aTrpB mutant polypeptide on a TrpB substrate, as determined in vivo or invitro, according to standard techniques. The biological activity of TrpBmutants is described herein as, for example, the ability to utilizeindole or analogs thereof and L-serine or L-threonine in the generationof NCAAs or UAAs. Other measurements are described in the examplesbelow.

One of skill in the art will appreciate that many conservativevariations of the nucleic acid constructs, which are disclosed, yield afunctionally identical construct. For example, owing to the degeneracyof the genetic code, “silent substitutions” (i.e., substitutions in anucleic acid sequence which do not result in an alteration in an encodedpolypeptide) are an implied feature of every nucleic acid sequence thatencodes an amino acid. Similarly, “conservative amino acidsubstitutions,” in one or a few amino acids in an amino acid sequenceare substituted with different amino acids with highly similarproperties, are also readily identified as being highly similar to adisclosed construct. Such conservative variations of each disclosedsequence are a feature of the polypeptides provided herein.

It will be appreciated by those skilled in the art that due to thedegeneracy of the genetic code, a multitude of nucleotide sequencesencoding mutant TrpBs of the disclosure may be produced, some of whichbear substantial identity to the nucleic acid sequences explicitlydisclosed herein (e.g., SEQ ID NO:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21,23, 25, 27, 29, 31, 33, 35, 37, and 39). For instance, codons AGA, AGG,CGA, CGC, CGG, and CGU all encode the amino acid arginine. Thus, atevery position in the nucleic acids of the disclosure where an arginineis specified by a codon, the codon can be altered to any of thecorresponding codons described above without altering the encodedpolypeptide. It is understood that U in an RNA sequence corresponds to Tin a DNA sequence.

“Conservative variants” are proteins or enzymes in which a given aminoacid residue has been changed without altering overall conformation andfunction of the protein or enzyme, including, but not limited to,replacement of an amino acid with one having similar properties,including polar or non-polar character, size, shape, and charge. Aminoacids other than those indicated as conserved may differ in a protein orenzyme so that the percent protein or amino acid sequence similaritybetween any two proteins of similar function may vary and can be, forexample, at least 30%, at least 50%, at least 70%, at least 80%, atleast 90%, at least 95%, at least 98%, or at least 99%, as determinedaccording to an alignment scheme. As referred to herein, “sequencesimilarity” means the extent to which nucleotide or protein sequencesare related. The extent of similarity between two sequences can be basedon percent sequence identity and/or conservation. “Sequence identity”herein means the extent to which two nucleotide or amino acid sequencesare invariant. “Sequence alignment” means the process of lining up twoor more sequences to achieve maximal levels of identity (and, in thecase of amino acid sequences, conservation) for the purpose of assessingthe degree of similarity. Numerous methods for aligning sequences andassessing similarity/identity are known in the art such as, for example,the Cluster Method, wherein similarity is based on the MEGALIGNalgorithm, as well as BLASTN, BLASTP, and FASTA (Lipman and Pearson,1985; Pearson and Lipman, 1988). When using all of these programs, thepreferred settings are those that result in the highest sequencesimilarity.

“Sequence identity” herein means the extent to which two nucleotide oramino acid sequences are invariant. “Sequence alignment” means theprocess of lining up two or more sequences to achieve maximal levels ofidentity (and, in the case of amino acid sequences, conservation) forthe purpose of assessing the degree of similarity. Numerous methods foraligning sequences and assessing similarity/identity are known in theart such as, for example, the Cluster Method, wherein similarity isbased on the MEGALIGN algorithm, as well as BLASTN, BLASTP, and FASTA(Lipman and Pearson, 1985; Pearson and Lipman, 1988). When using all ofthese programs, the preferred settings are those that result in thehighest sequence similarity. For example, the “identity” or “percentidentity” with respect to a particular pair of aligned amino acidsequences can refer to the percent amino acid sequence identity that isobtained by ClustalW analysis (version W 1.8 available from EuropeanBioinformatics Institute, Cambridge, UK), counting the number ofidentical matches in the alignment and dividing such number of identicalmatches by the greater of (i) the length of the aligned sequences, and(ii) 96, and using the following default ClustalW parameters to achieveslow/accurate pairwise alignments—Gap Open Penalty: 10; Gap ExtensionPenalty: 0.10; Protein weight matrix: Gonnet series; DNA weight matrix:IUB; Toggle Slow/Fast pairwise alignments=SLOW or FULL Alignment.

Two sequences are “optimally aligned” when they are aligned forsimilarity scoring using a defined amino acid substitution matrix (e.g.,BLOSUM62), gap existence penalty and gap extension penalty so as toarrive at the highest score possible for that pair of sequences. Aminoacid substitution matrices and their use in quantifying the similaritybetween two sequences are well-known in the art and described, e.g., inDayhoff et al. (1978) “A model of evolutionary change in proteins” in“Atlas of Protein Sequence and Structure,” Vol. 5, Suppl. 3 (ed. M. O.Dayhoff), pp. 345-352. Natl. Biomed. Res. Found., Washington, D.C. andHenikoff et al. (1992) Proc. Nat'l. Acad. Sci. USA 89: 10915-10919 (eachof which is incorporated by reference). The BLOSUM62 matrix is oftenused as a default scoring substitution matrix in sequence alignmentprotocols such as Gapped BLAST 2.0. The gap existence penalty is imposedfor the introduction of a single amino acid gap in one of the alignedsequences, and the gap extension penalty is imposed for each additionalempty amino acid position inserted into an already opened gap. Thealignment is defined by the amino acids positions of each sequence atwhich the alignment begins and ends, and optionally by the insertion ofa gap or multiple gaps in one or both sequences so as to arrive at thehighest possible score. While optimal alignment and scoring can beaccomplished manually, the process is facilitated by the use of acomputer-implemented alignment algorithm, e.g., gapped BLAST 2.0,described in Altschul et al. (1997) Nucl. Acids Res. 25: 3389-3402(incorporated by reference herein), and made available to the public atthe National Center for Biotechnology Information (NCBI) Website([www.]ncbi.nlm.nih.gov). Optimal alignments, including multiplealignments, can be prepared using, e.g., PSI-BLAST, available throughthe NCB1 website and described by Altschul et al. (1997) Nucl. AcidsRes. 25:3389-3402 (incorporated by reference herein).

With respect to an amino acid sequence that is optimally aligned with areference sequence, an amino acid residue “corresponds to” the positionin the reference sequence with which the residue is paired in thealignment. The “position” is denoted by a number that sequentiallyidentifies each amino acid in the reference sequence based on itsposition relative to the N-terminus. For example, in SEQ ID NO:2,position 12 is P, position 13 is E, etc. When a test sequence isoptimally aligned with SEQ ID NO:2, a residue in the test sequence thataligns with the P at position 12 is said to “correspond to position 12”of SEQ ID NO:2. Owing to deletions, insertion, truncations, fusions,etc., that must be taken into account when determining an optimalalignment, in general the amino acid residue number in a test sequenceas determined by simply counting from the N-terminal end will notnecessarily be the same as the number of its corresponding position inthe reference sequence. For example, in a case where there is a deletionin an aligned test sequence, there will be no amino acid thatcorresponds to a position in the reference sequence at the site ofdeletion. Where there is an insertion in an aligned reference sequence,that insertion will not correspond to any amino acid position in thereference sequence. In the case of truncations or fusions there can bestretches of amino acids in either the reference or aligned sequencethat do not correspond to any amino acid in the corresponding sequence.

Non-conservative modifications of a particular polypeptide are those,which substitute any amino acid not characterized as a conservativesubstitution. For example, any substitution which crosses the bounds ofthe six groups set forth above. These include substitutions of basic oracidic amino acids for neutral amino acids, (e.g., Asp, Glu, Asn, or Glnfor Val, Ile, Leu or Met), aromatic amino acid for basic or acidic aminoacids (e.g., Phe, Tyr or Trp for Asp, Asn, Glu or Gln) or any othersubstitution not replacing an amino acid with a like amino acid. Basicside chains include lysine (K), arginine (R), histidine (H); acidic sidechains include aspartic acid (D), glutamic acid (E); uncharged polarside chains include glycine (G), asparagine (N), glutamine (Q), serine(S), threonine (T), tyrosine (Y), cysteine (C); nonpolar side chainsinclude alanine (A), valine (V), leucine (L), isoleucine (I), proline(P), phenylalanine (F), methionine (M), tryptophan (W); beta-branchedside chains include threonine (T), valine (V), isoleucine (I); aromaticside chains include tyrosine (Y), phenylalanine (F), tryptophan (W),histidine (H).

Accordingly, some amino acid residues at specific positions in apolypeptide are “excluded” from conservative amino acid substitutions.Instead, these restricted amino acids are generally chosen from aspecific group or selected amino acids or are not substituted or mutatedat all.

A polynucleotide, polypeptide, or other component is “isolated” or“purified” when it is partially or completely separated from componentswith which it is normally associated (other proteins, nucleic acids,cells, synthetic reagents, etc.). A nucleic acid or polypeptide is“recombinant” when it is artificial or engineered, or derived from anartificial or engineered protein or nucleic acid through the process ofmutation. For example, a polynucleotide that is inserted into a vectoror any other heterologous location, e.g., in a genome of a recombinantorganism, such that it is not associated with nucleotide sequences thatnormally flank the polynucleotide as it is found in nature is arecombinant polynucleotide. A protein expressed in vitro or in vivo froma recombinant polynucleotide is an example of a recombinant polypeptide.Likewise, a polynucleotide sequence that does not appear in nature, forexample a variant or engineered mutant of a naturally occurring gene, isrecombinant. For example, an “isolated” nucleic acid molecule is onewhich is separated from other nucleic acid molecules which are presentin the natural source of the nucleic acid. For example, with regards togenomic DNA, the term “isolated” includes nucleic acid molecules whichare separated from the chromosome with which the genomic DNA isnaturally associated. Typically, an “isolated” nucleic acid is free ofsequences which naturally flank the nucleic acid (i.e., sequenceslocated at the 5′ and 3′ ends of the nucleic acid) in the genomic DNA ofthe organism from which the nucleic acid is derived. For example, invarious embodiments, the isolated nucleic acid molecule can contain lessthan about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb or 0.1 kb of nucleotidesequences which naturally flank the nucleic acid molecule in genomic DNAof the cell from which the nucleic acid is derived. Moreover, an“isolated” nucleic acid molecule, such as a cDNA molecule, can besubstantially free of other cellular material, or culture medium whenproduced by recombinant techniques, or substantially free of chemicalprecursors or other chemicals when chemically synthesized.

The disclosure envisions multi-unit polypeptides. Such a multi-unitpolypeptide would comprise for example: TrpA-mTrpB-mTrpB-TrpA. Thetryptophan-α domain (and sequences thereof) of TrpS for each ofPyrococcus furiosus, Archaeoglobus fulgidus, Thermotoga maritima, andEscherichia coli are well known in the art.

In other embodiments, isolated nucleic acid molecules are provided. Inone embodiment, the disclosure provides a novel family of isolated orrecombinant polynucleotides referred to herein as “TrpB mutantpolynucleotides” or “TrpB mutant nucleic acid molecules.” TrpB mutantpolynucleotide sequences are characterized by the ability to encode aTrpB mutant polypeptide. In general, the disclosure includes anynucleotide sequence that encodes any of the TrpB mutant polypeptidesdescribed herein. In some aspects of the disclosure, a TrpB mutantpolynucleotide that encodes a TrpB mutant polypeptide with TrpB mutantactivity is provided. The terms “polynucleotide,” “nucleotide sequence,”and “nucleic acid molecule” are used to refer to a polymer ofnucleotides (A, C, T, U, G, etc. or naturally occurring or artificialnucleotide analogues), e.g., DNA or RNA, or a representation thereof,e.g., a character string, etc., depending on the relevant context. Agiven polynucleotide or complementary polynucleotide can be determinedfrom any specified nucleotide sequence.

In one embodiment, the TrpB mutant polynucleotides comprise recombinantor isolated forms of naturally occurring nucleic acids isolated from anorganism, which have been mutated by, for example, directed evolution.Exemplary TrpB polynucleotides include those that encode the wild-typepolypeptides set forth in SEQ ID NO: 2, 4, 6, or 8. In another aspect ofthe disclosure, TrpB mutant polynucleotides are produced bydiversifying, e.g., recombining and/or mutating one or more naturallyoccurring, isolated, or recombinant TrpB polynucleotides. As describedin more detail elsewhere herein, it is often possible to generatediversified TrpB mutant polynucleotides encoding TrpB mutantpolypeptides with superior functional attributes, e.g., increasedcatalytic function, increased stability, novel substrate or productproduction, or higher expression level, than a TrpB polynucleotide usedas a substrate or parent in the diversification process. Exemplarypolynucleotides include those that encode the TrpB mutant polypeptidesset forth in SEQ ID NO: 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31,33, 35, 37 or 39.

The polynucleotides of the disclosure have a variety of uses in, forexample recombinant production (i.e., expression) of the TrpB mutantpolypeptides of the disclosure and as substrates for further diversitygeneration, e.g., recombination reactions or mutation reactions toproduce new and/or improved TrpB mutant homologues, and the like.

It is important to note that certain specific, substantial, and credibleutilities of TrpB mutant polynucleotides do not require that thepolynucleotide encodes a polypeptide with substantial TrpB mutantactivity or even TrpB mutant activity. For example, TrpB mutantpolynucleotides that do not encode active enzymes can be valuablesources of parental polynucleotides for use in diversificationprocedures to arrive at TrpB mutant polynucleotide with desirablefunctional properties (e.g., high k_(cat) or k_(cat)/K_(M), low K_(M),high stability toward heat or other environmental factors, hightranscription or translation rates, resistance to proteolytic cleavage,etc.).

TrpB mutant polynucleotides, including nucleotide sequences that encodeTrpB polypeptides and variants thereof, fragments of TrpB mutantpolypeptides, related fusion proteins, or functional equivalentsthereof, are used in recombinant DNA molecules that direct theexpression of the TrpB mutant polypeptides in appropriate host cells,such as bacterial cells. Due to the inherent degeneracy of the geneticcode, other nucleic acid sequences which encode substantially the sameor a functionally equivalent amino acid sequence can also be used toclone and express the TrpB mutant polynucleotides.

The term “host cell”, as used herein, includes any cell type which issusceptible to transformation with a nucleic acid construct. The term“transformation” means the introduction of a foreign (i.e., extrinsic orextracellular) gene, DNA or RNA sequence to a host cell, so that thehost cell will express the introduced gene or sequence to produce adesired substance, typically a protein or enzyme coded by the introducedgene or sequence. The introduced gene or sequence may include regulatoryor control sequences, such as start, stop, promoter, signal, secretion,or other sequences used by the genetic machinery of the cell. A hostcell that receives and expresses introduced DNA or RNA has been“transformed” and is a “transformant” or a “clone.” The DNA or RNAintroduced to a host cell can come from any source, including cells ofthe same genus or species as the host cell, or cells of a differentgenus or species.

As will be understood by those of skill in the art, it can beadvantageous to modify a coding sequence to enhance its expression in aparticular host. The genetic code is redundant with 64 possible codons,but most organisms preferentially use a subset of these codons. Thecodons that are utilized most often in a species are called optimalcodons, and those not utilized very often are classified as rare orlow-usage codons (see, e.g., Zhang et al. (1991) Gene 105:61-72;incorporated by reference herein). Codons can be substituted to reflectthe preferred codon usage of the host, a process sometimes called “codonoptimization” or “controlling for species codon bias.”

Optimized coding sequences containing codons preferred by a particularprokaryotic or eukaryotic host (see also, Murray et al. (1989) Nucl.Acids Res. 17:477-508; incorporated by reference herein) can beprepared, for example, to increase the rate of translation or to producerecombinant RNA transcripts having desirable properties, such as alonger half-life, as compared with transcripts produced from anon-optimized sequence. Translation stop codons can also be modified toreflect host preference. For example, preferred stop codons for S.cerevisiae and mammals are UAA and UGA, respectively. The preferred stopcodon for monocotyledonous plants is UGA, whereas insects and E. coliprefer to use UAA as the stop codon (Dalphin et al. (1996) Nucl. AcidsRes. 24: 216-218; incorporated by reference herein). Methodology foroptimizing a nucleotide sequence for expression in a plant is provided,for example, in U.S. Pat. No. 6,015,891, and the references citedtherein (incorporated herein by reference).

Accordingly, in some embodiments, nucleic acid molecules of thedisclosure include: (a) a nucleic acid molecule which encodes apolypeptide comprising the amino acid sequence set forth in SEQ IDNO:10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38 or 40; (b)a nucleic acid molecule which encodes a polypeptide consisting of theamino acid sequence set forth in SEQ ID NO: 10, 12, 14, 16, 18, 20, 22,24, 26, 28, 30, 32, 34, 36, 38 or 40; (c) a nucleic acid molecule whichhybridizes under stringent conditions to a polynucleotide consisting ofSEQ ID NO:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33,35, 37, or 39 and which encodes a TrpB mutant polypeptide that as anindependent subunit catalyze the production of NCAAs or UAAs from anindole or indole derivative and L-serine or L-threonine; or (d) anucleic acid molecule which hybridizes under stringent conditions to apolynucleotide consisting of SEQ ID NO:1, 3, 5, 7, 9, 11, 13, 15, 17,19, 21, 23, 25, 27, 29, 31, 33, 35, 37, or 39 and which encodes apolypeptide that comprises the amino acid sequence set forth in SEQ IDNO: 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38 or 40.

In one embodiment, an isolated nucleic acid molecule that includes anucleic acid molecule of the disclosure and a nucleotide sequenceencoding a heterologous polypeptide or peptide is provided. For example,a coding sequence for a tag (e.g., a polyHis Tag) can be linked to apolynucleotide of the disclosure.

In general, the disclosure includes any TrpB mutant polypeptide encodedby a modified TrpB polynucleotide derived by mutation, recursivesequence recombination, and/or diversification of the polynucleotidesequences described herein, wherein the polypeptide has novel substratespecificity (e.g., L-threonine), can catalyze a reaction independent ofthe TrpA subunit using either L-threonine or L-serine and which canproduce NCAAs or UAAs.

A nucleic acid molecule of the disclosure, e.g., a nucleic acid moleculethat encodes a polypeptide set forth in any of SEQ NOs:2, 4, 6, 8, 10,12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38 or 40, or havingthe nucleotide sequence of set forth in any of SEQ ID NOs:1, 3, 5, 7, 9,11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, or 39, or aportion thereof, can be isolated using standard molecular biologytechniques and the sequence information provided herein.

A nucleic acid of the disclosure can be amplified using cDNA, mRNA oralternatively, genomic DNA, as a template and appropriateoligonucleotide primers according to standard PCR amplificationtechniques. The nucleic acid so amplified can be cloned into anappropriate vector and characterized by DNA sequence analysis.Furthermore, oligonucleotides corresponding to nucleotide sequences canbe prepared by standard synthetic techniques, e.g., using an automatedDNA synthesizer. In some embodiments, an isolated nucleic acid moleculeof the disclosure comprises a nucleic acid molecule which is acomplement of a nucleotide sequence encoding a polypeptide set forth inany of SEQ NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30,32, 34, 36, 38 or 40. In still another embodiment, an isolated nucleicacid molecule of the disclosure comprises a nucleotide sequence which isat least about 50%, 54%, 55%, 60%, 62%, 65%, 70%, 75%, 78%, 80%, 85%,86%, 90%, 95%, 97%, 98% or more identical to the nucleotide sequenceencoding a polypeptide set forth in any of SEQ NOs: 2, 4, 6, 8, 10, 12,14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38 or 40, or having thenucleotide sequence set forth in any of SEQ ID NOs:1, 3, 5, 7, 9, 11,13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, or 39, or a portionof any of these nucleotide sequences.

In another embodiment, an isolated nucleic acid molecule of thedisclosure hybridizes under stringent conditions to a nucleic acidmolecule consisting the nucleotide sequence encoding a polypeptide setforth in any of SEQ NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26,28, 30, 32, 34, 36, 38 or 40, or having the nucleotide sequence setforth in any of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23,25, 27, 29, 31, 33, 35, 37, or 39. Nucleic acid molecules are“hybridizable” to each other when at least one strand of onepolynucleotide can anneal to another polynucleotide under definedstringency conditions. Stringency of hybridization is determined, e.g.,by (a) the temperature at which hybridization and/or washing isperformed, and (b) the ionic strength and polarity (e.g., formamide) ofthe hybridization and washing solutions, as well as other parameters.Hybridization requires that the two polynucleotides containsubstantially complementary sequences; depending on the stringency ofhybridization, however, mismatches may be tolerated. Typically,hybridization of two sequences at high stringency (such as, for example,in an aqueous solution of 0.5×SSC at 65° C.) requires that the sequencesexhibit some high degree of complementarity over their entire sequence.Conditions of intermediate stringency (such as, for example, an aqueoussolution of 2×SSC at 65° C.) and low stringency (such as, for example,an aqueous solution of 2×SSC at 55° C.) require correspondingly lessoverall complementarity between the hybridizing sequences (1×SSC is 0.15M NaCl, 0.015 M Na citrate). Nucleic acid molecules that hybridizeinclude those which anneal under suitable stringency conditions andwhich encode polypeptides or enzymes having the same function, such asthe ability to catalyze the conversion of an indole or indole derivativeand L-serine or L-threonine to a NCAA or UAA. Further, the term“hybridizes under stringent conditions” is intended to describeconditions for hybridization and washing under which nucleotidesequences at least 60% or greater in homology to each other typicallyremain hybridized to each other. Preferably, the conditions are suchthat sequences at least about 70%, more preferably at least about 80%,even more preferably at least about 85% or 90% homologous to each othertypically remain hybridized to each other.

The skilled artisan will appreciate that changes can be introduced bymutation into the nucleotide sequences of any nucleic acid sequenceencoding a polypeptide set forth in any of SEQ NOs: 2, 4, 6, 8, 10, 12,14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38 or 40, or having thenucleotide sequence set forth in any of SEQ ID NOs: 1, 3, 5, 7, 9, 11,13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, or 39, therebyleading to changes in the amino acid sequence of the encoded proteins.In some cases the alteration will lead to altered function of thepolypeptide. In other cases the change will not alter the functionalability of the encoded polypeptide.

Also contemplated are those situations where it is desirable to alterthe activity of a parent polypeptide such that the polypeptide has newor increased activity on a particular substrate. It is understood thatthese amino acid substitutions will generally not constitute“conservative” substitutions. Instead, these substitutions constitutenon-conservative substitutions introduced into a sequence in order toobtain a new or improved activity. For example, the polypeptides setforth SEQ ID NOs: 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34,36, 38 and 40 describe specific amino acid substitutions that contributeto the alteration of the activity of a parent polypeptide.

It is also understood that an isolated nucleic acid molecule encoding apolypeptide homologous to the polypeptides of SEQ ID NOs: 2, 4, 6, 8,10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, or 40 can becreated by introducing one or more nucleotide substitutions, additions,or deletions into the nucleotide sequence encoding the particularpolypeptide, such that one or more amino acid substitutions, additionsor deletions are introduced into the encoded protein. Mutations can beintroduced into the nucleic acid sequence by standard techniques, suchas site-directed mutagenesis and PCR-mediated mutagenesis. In contrastto those positions where it may be desirable to make a non-conservativeamino acid substitutions (see above), in some positions it is preferableto make conservative amino acid substitutions.

Mutational methods of generating diversity include, for example,site-directed mutagenesis (Ling et al. (1997) “Approaches to DNAmutagenesis: an overview” Anal Biochem. 254(2): 157-178; Dale et al.(1996) “Oligonucleotide-directed random mutagenesis using thephosphorothioate method” Methods Mol. Biol. 57:369-374; Smith (1985) “Invitro mutagenesis” Ann. Rev. Genet. 19:423-462; Botstein & Shortle(1985) “Strategies and applications of in vitro mutagenesis” Science229:1193-1201; Carter (1986) “Site-directed mutagenesis” Biochem. J.237:1-7; and Kunkel (1987) “The efficiency of oligonucleotide directedmutagenesis” in Nucleic Acids & Molecular Biology (Eckstein, F. andLilley, D. M. J. eds., Springer Verlag, Berlin)); mutagenesis usinguracil containing templates (Kunkel (1985) “Rapid and efficientsite-specific mutagenesis without phenotypic selection” Proc. Natl.Acad. Sci. USA 82:488-492; Kunkel et al. (1987) “Rapid and efficientsite-specific mutagenesis without phenotypic selection” Methods inEnzymol. 154, 367-382; and Bass et al. (1988) “Mutant Trp repressorswith new DNA-binding specificities” Science 242:240-245);oligonucleotide-directed mutagenesis (Methods in Enzymol. 100: 468-500(1983); Methods in Enzymol. 154: 329-350 (1987); Zoller & Smith (1982)“Oligonucleotide-directed mutagenesis using M13-derived vectors: anefficient and general procedure for the production of point mutations inany DNA fragment” Nucleic Acids Res. 10:6487-6500; Zoller & Smith (1983)“Oligonucleotide-directed mutagenesis of DNA fragments cloned into M13vectors” Methods in Enzymol. 100:468-500; and Zoller & Smith (1987)“Oligonucleotide-directed mutagenesis: a simple method using twooligonucleotide primers and a single-stranded DNA template” Methods inEnzymol. 154:329-350); phosphorothioate-modified DNA mutagenesis (Tayloret al. (1985) “The use of phosphorothioate-modified DNA in restrictionenzyme reactions to prepare nicked DNA” Nucl. Acids Res. 13: 8749-8764;Taylor et al. (1985) “The rapid generation of oligonucleotide-directedmutations at high frequency using phosphorothioate-modified DNA” Nucl.Acids Res. 13: 8765-8787; Nakamaye & Eckstein (1986) “Inhibition ofrestriction endonuclease Nci I cleavage by phosphorothioate groups andits application to oligonucleotide-directed mutagenesis” Nucl. AcidsRes. 14: 9679-9698; Sayers et al. (1988) “Y-T Exonucleases inphosphorothioate-based oligonucleotide-directed mutagenesis” Nucl. AcidsRes. 16:791-802; and Sayers et al. (1988) “Strand specific cleavage ofphosphorothioate-containing DNA by reaction with restrictionendonucleases in the presence of ethidium bromide” Nucl. Acids Res. 16:803-814); mutagenesis using gapped duplex DNA (Kramer et al. (1984) “Thegapped duplex DNA approach to oligonucleotide-directed mutationconstruction” Nucl. Acids Res. 12: 9441-9456; Kramer & Fritz (1987)Methods in Enzymol. “Oligonucleotide-directed construction of mutationsvia gapped duplex DNA” 154:350-367; Kramer et al. (1988) “Improvedenzymatic in vitro reactions in the gapped duplex DNA approach tooligonucleotide-directed construction of mutations” Nucl. Acids Res. 16:7207; and Fritz et al. (1988) “Oligonucleotide-directed construction ofmutations: a gapped duplex DNA procedure without enzymatic reactions invitro” Nucl. Acids Res. 16: 6987-6999) (each of which is incorporated byreference).

Additional suitable methods include point mismatch repair (Kramer et al.(1984) “Point Mismatch Repair” Cell 38:879-887), mutagenesis usingrepair-deficient host strains (Carter et al. (1985) “Improvedoligonucleotide site-directed mutagenesis using M13 vectors” Nucl. AcidsRes. 13: 4431-4443; and Carter (1987) “Improved oligonucleotide-directedmutagenesis using M13 vectors” Methods in Enzymol. 154: 382-403),deletion mutagenesis (Eghtedarzadeh & Henikoff (1986) “Use ofoligonucleotides to generate large deletions” Nucl. Acids Res. 14:5115), restriction-selection and restriction-purification (Wells et al.(1986) “Importance of hydrogen-bond formation in stabilizing thetransition state of subtilisin” Phil. Trans. R. Soc. Lond. A 317:415-423), mutagenesis by total gene synthesis (Nambiar et al. (1984)“Total synthesis and cloning of a gene coding for the ribonuclease Sprotein” Science 223: 1299-1301; Sakamar and Khorana (1988) “Totalsynthesis and expression of a gene for the α-subunit of bovine rod outersegment guanine nucleotide-binding protein (transducin)” Nucl. AcidsRes. 14: 6361-6372; Wells et al. (1985) “Cassette mutagenesis: anefficient method for generation of multiple mutations at defined sites”Gene 34:315-323; and Grundstrom et al. (1985) “Oligonucleotide-directedmutagenesis by microscale ‘shot-gun’ gene synthesis” Nucl. Acids Res.13: 3305-3316); double-strand break repair (Mandecki (1986); Arnold(1993) “Protein engineering for unusual environments” Current Opinion inBiotechnology 4:450-455; and “Oligonucleotide-directed double-strandbreak repair in plasmids of Escherichia coli: a method for site-specificmutagenesis” Proc. Natl. Acad. Sci. USA, 83:7177-7181) (each of which isincorporated by reference). Additional details on many of the abovemethods can be found in Methods in Enzymology Volume 154, which alsodescribes useful controls for trouble-shooting problems with variousmutagenesis methods.

Additional details regarding various diversity generating methods can befound in the following U.S. patents, PCT publications, and EPOpublications: U.S. Pat. No. 5,605,793 to Stemmer (Feb. 25, 1997),“Methods for In vitro Recombination;” U.S. Pat. No. 5,811,238 to Stemmeret al. (Sep. 22, 1998) “Methods for Generating Polynucleotides havingDesired Characteristics by Iterative Selection and Recombination;” U.S.Pat. No. 5,830,721 to Stemmer et al. (Nov. 3, 1998), “DNA Mutagenesis byRandom Fragmentation and Reassembly;” U.S. Pat. No. 5,834,252 toStemmer, et al. (Nov. 10, 1998) “End-Complementary Polymerase Reaction;”U.S. Pat. No. 5,837,458 to Minshull, et al. (Nov. 17, 1998), “Methodsand Compositions for Cellular and Metabolic Engineering;” WO 95/22625,Stemmer and Crameri, “Mutagenesis by Random Fragmentation andReassembly;” WO 96/33207 by Stemmer and Lipschutz “End ComplementaryPolymerase Chain Reaction;” WO 97/20078 by Stemmer and Crameri “Methodsfor Generating Polynucleotides having Desired Characteristics byIterative Selection and Recombination;” WO 97/35966 by Minshull andStemmer, “Methods and Compositions for Cellular and MetabolicEngineering;” WO 99/41402 by Punnonen et al. “Targeting of GeneticVaccine Vectors;” WO 99/41383 by Punnonen et al. “Antigen LibraryImmunization;” WO 99/41369 by Punnonen et al. “Genetic Vaccine VectorEngineering;” WO 99/41368 by Punnonen et al. “Optimization ofImmunomodulatory Properties of Genetic Vaccines;” EP 752008 by Stemmerand Crameri, “DNA Mutagenesis by Random Fragmentation and Reassembly;”EP 0932670 by Stemmer “Evolving Cellular DNA Uptake by RecursiveSequence Recombination;” WO 99/23107 by Stemmer et al., “Modification ofVirus Tropism and Host Range by Viral Genome Shuffling;” WO 99/21979 byApt et al., “Human Papillomavirus Vectors;” WO 98/31837 by del Cardayreet al. “Evolution of Whole Cells and Organisms by Recursive SequenceRecombination;” WO 98/27230 by Patten and Stemmer, “Methods andCompositions for Polypeptide Engineering;” WO 98/13487 by Stemmer etal., “Methods for Optimization of Gene Therapy by Recursive SequenceShuffling and Selection;” WO 00/00632, “Methods for Generating HighlyDiverse Libraries;” WO 00/09679, “Methods for Obtaining in vitroRecombined Polynucleotide Sequence Banks and Resulting Sequences;” WO98/42832 by Arnold et al., “Recombination of Polynucleotide SequencesUsing Random or Defined Primers;” WO 99/29902 by Arnold et al., “Methodfor Creating Polynucleotide and Polypeptide Sequences;” WO 98/41653 byVind, “An in vitro Method for Construction of a DNA Library;” WO98/41622 by Borchert et al., “Method for Constructing a Library UsingDNA Shuffling;” WO 98/42727 by Pati and Zarling, “Sequence Alterationsusing Homologous Recombination;” WO 00/18906 by Patten et al.,“Shuffling of Codon-Altered Genes;” WO 00/04190 by del Cardayre et al.“Evolution of Whole Cells and Organisms by Recursive Recombination;” WO00/42561 by Crameri et al., “Oligonucleotide Mediated Nucleic AcidRecombination;” WO 00/42559 by Selifonov and Stemmer “Methods ofPopulating Data Structures for Use in Evolutionary Simulations;” WO00/42560 by Selifonov et al., “Methods for Making Character Strings,Polynucleotides & Polypeptides Having Desired Characteristics;” WO01/23401 by Welch et al., “Use of Codon-Varied Oligonucleotide Synthesisfor Synthetic Shuffling;” and WO 01/64864 “Single-Stranded Nucleic AcidTemplate-Mediated Recombination and Nucleic Acid Fragment Isolation” byAffholter (each of which is incorporated by reference).

Also provided are recombinant constructs comprising one or more of thenucleic acid sequences as broadly described above. The constructscomprise a vector, such as, a plasmid, a cosmid, a phage, a virus, abacterial artificial chromosome (BAC), a yeast artificial chromosome(YAC), or the like, into which a nucleic acid sequence of the disclosurehas been inserted, in a forward or reverse orientation. In a preferredaspect of this embodiment, the construct further comprises regulatorysequences including, for example, a promoter operably linked to thesequence. Large numbers of suitable vectors and promoters are known tothose of skill in the art, and are commercially available.

Accordingly, in other embodiments, vectors that include a nucleic acidmolecule of the invention are provided. In other embodiments, host cellstransfected with a nucleic acid molecule of the invention, or a vectorthat includes a nucleic acid molecule of the invention, are provided.Host cells include eucaryotic cells such as yeast cells, insect cells,or animal cells. Host cells also include prokaryotic cells such asbacterial cells.

The terms “vector”, “vector construct” and “expression vector” mean thevehicle by which a DNA or RNA sequence (e.g. a foreign gene) can beintroduced into a host cell, so as to transform the host and promoteexpression (e.g. transcription and translation) of the introducedsequence. Vectors typically comprise the DNA of a transmissible agent,into which foreign DNA encoding a protein is inserted by restrictionenzyme technology. A common type of vector is a “plasmid”, whichgenerally is a self-contained molecule of double-stranded DNA that canreadily accept additional (foreign) DNA and which can be readilyintroduced into a suitable host cell. A large number of vectors,including plasmid and fungal vectors, have been described forreplication and/or expression in a variety of eukaryotic and prokaryotichosts. Non-limiting examples include pKK plasmids (Clonetech), pUCplasmids, pET plasmids (Novagen, Inc., Madison, Wis.), pRSET or pREPplasmids (Invitrogen, San Diego, Calif.), or pMAL plasmids (New EnglandBiolabs, Beverly, Mass.), and many appropriate host cells, using methodsdisclosed or cited herein or otherwise known to those skilled in therelevant art. Recombinant cloning vectors will often include one or morereplication systems for cloning or expression, one or more markers forselection in the host, e.g., antibiotic resistance, and one or moreexpression cassettes.

The terms “express” and “expression” mean allowing or causing theinformation in a gene or DNA sequence to become manifest, for exampleproducing a protein by activating the cellular functions involved intranscription and translation of a corresponding gene or DNA sequence. ADNA sequence is expressed in or by a cell to form an “expressionproduct” such as a protein. The expression product itself, e.g. theresulting protein, may also be said to be “expressed” by the cell. Apolynucleotide or polypeptide is expressed recombinantly, for example,when it is expressed or produced in a foreign host cell under thecontrol of a foreign or native promoter, or in a native host cell underthe control of a foreign promoter.

Polynucleotides provided herein can be incorporated into any one of avariety of expression vectors suitable for expressing a polypeptide.Suitable vectors include chromosomal, nonchromosomal and synthetic DNAsequences, e.g., derivatives of SV40; bacterial plasmids; phage DNA;baculovirus; yeast plasmids; vectors derived from combinations ofplasmids and phage DNA, viral DNA such as vaccinia, adenovirus, fowl poxvirus, pseudorabies, adenovirus, adeno-associated viruses, retrovirusesand many others. Any vector that transduces genetic material into acell, and, if replication is desired, which is replicable and viable inthe relevant host can be used.

Vectors can be employed to transform an appropriate host to permit thehost to express a mutant TrpB polypeptide or protein. Examples ofappropriate expression hosts include: bacterial cells, such as E. coli,B. subtilis, Streptomyces, and Salmonella typhimurium; fungal cells,such as Saccharomyces cerevisiae, Pichia pastoris, and Neurosporacrassa; insect cells such as Drosophila and Spodoptera frugiperda;mammalian cells such as CHO, COS, BHK, HEK 293 br Bowes melanoma; orplant cells or explants, etc.

In bacterial systems, a number of expression vectors may be selecteddepending upon the use intended for the mutant TrpB polypeptide. Forexample, when large quantities of mutant TrpB polypeptide or fragmentsthereof are needed for commercial production or for induction ofantibodies, vectors which direct high-level expression of fusionproteins that are readily purified can be desirable. Such vectorsinclude, but are not limited to, multifunctional E. coli cloning andexpression vectors such as BLUESCRIPT (Stratagene), in which the mutantTrpB polypeptide coding sequence may be ligated into the vector in-framewith sequences for the amino-terminal Met and the subsequent 7 residuesof beta-galactosidase so that a hybrid protein is produced; pIN vectors(Van Heeke & Schuster (1989) J. Biol. Chem. 264: 5503-5509); pET vectors(Novagen, Madison Wis.); and the like.

Similarly, in the yeast Saccharomyces cerevisiae a number of vectorscontaining constitutive or inducible promoters such as alpha factor,alcohol oxidase and PGH may be used for production of the TrpBpolypeptides of the invention. For reviews, see Ausubel (supra) andGrant et al. (1987) Methods in Enzymology 153:516-544 (incorporatedherein by reference).

Also provided are engineered host cells that are transduced (transformedor transfected) with a vector provided herein (e.g., a cloning vector oran expression vector), as well as the production of polypeptides of thedisclosure by recombinant techniques. The vector may be, for example, aplasmid, a viral particle, a phage, etc. The engineered host cells canbe cultured in conventional nutrient media modified as appropriate foractivating promoters, selecting transformants, etc. Culture conditions,such as temperature, pH and the like, are those previously used with thehost cell selected for expression, and will be apparent to those skilledin the art and in the references cited herein, including, e.g.,Sambrook, Ausubel and Berger, as well as e.g., Freshney (1994) Cultureof Animal Cells: A Manual of Basic Technique, 3rd ed. (Wiley-Liss, NewYork) and the references cited therein.

In other embodiments, methods for producing a cell that converts anindole or indole derivative and L-serine or L-threonine to a NCAA orUAA, are provided. Such methods generally include transforming a cellwith an isolated nucleic acid molecule (or vector containing the same)encoding a mutant TrpB polypeptide of the disclosure.

In other embodiments, methods for producing NCAAs or UAAs are provided.The methods include: (a) providing a cell containing a nucleic acidconstruct comprising a nucleotide sequence that encodes a mutant TrpB,(b) culturing the cell in the presence of a suitable indole or indolederivative and L-serine or L-threonine and under conditions where themutant TrpB is expressed at an effective level; and (c) producing anNCAA or UAA.

In another embodiment, methods of producing NCAAs or UAAs are provided.The method includes (a) providing L-serine or L-threonine, an indole orindole derivative, and a mutant TrpB of the disclosure. Admixing thecomponents for sufficient time and under suitable conditions to producethe NCAA or UAA.

In another embodiment, methods of producing β-methyl-tryptophan oranalogs thereof are provided. The method includes (a) providingL-threonine, an indole or indole derivative, and a mutant TrpB of thedisclosure. Admixing the components for sufficient time and undersuitable conditions to produce the β-methyl-tryptophan or analog. Thedisclosure provides that indole or derivatives thereof in, for example,the left column below when combined with L-threonine and a mutant TrpBof the disclosure can produce the β-methyl-tryptophan or analog in thecorresponding right column.

As previously discussed, general texts which describe molecularbiological techniques useful herein, including the use of vectors,promoters and many other relevant topics, include Berger and Kimmel,Guide to Molecular Cloning Techniques, Methods in Enzymology Volume 152,(Academic Press, Inc., San Diego, Calif.) (“Berger”); Sambrook et al.,Molecular Cloning—A Laboratory Manual, 2d ed., Vol. 1-3, Cold SpringHarbor Laboratory, Cold Spring Harbor, N.Y., 1989 (“Sambrook”) andCurrent Protocols in Molecular Biology, F. M. Ausubel et al., eds.,Current Protocols, a joint venture between Greene Publishing Associates,Inc. and John Wiley & Sons, Inc., (supplemented through 1999)(“Ausubel”) (each of which is incorporated by reference). Examples ofprotocols sufficient to direct persons of skill through in vitroamplification methods, including the polymerase chain reaction (PCR),the ligase chain reaction (LCR), Qβ-replicase amplification and otherRNA polymerase mediated techniques (e.g., NASBA), e.g., for theproduction of the homologous nucleic acids of the invention are found inBerger, Sambrook, and Ausubel, as well as in Mullis et al. (1987) U.S.Pat. No. 4,683,202; Innis et al., eds. (1990) PCR Protocols: A Guide toMethods and Applications (Academic Press Inc. San Diego, Calif.)(“Innis”); Arnheim & Levinson (Oct. 1, 1990) C&EN 36-47; The Journal OfNIH Research (1991) 3: 81-94; Kwoh et al. (1989) Proc. Natl. Acad. Sci.USA 86: 1173; Guatelli et al. (1990) Proc. Nat'l. Acad. Sci. USA 87:1874; Lomell et al. (1989) J. Clin. Chem 35: 1826; Landegren et al.(1988) Science 241: 1077-1080; Van Brunt (1990) Biotechnology 8:291-294; Wu and Wallace (1989) Gene 4:560; Barringer et al. (1990) Gene89:117; and Sooknanan and Malek (1995) Biotechnology 13: 563-564 (eachof which is incorporated by reference). Improved methods for cloning invitro amplified nucleic acids are described in Wallace et al., U.S. Pat.No. 5,426,039. Improved methods for amplifying large nucleic acids byPCR are summarized in Cheng et al. (1994) Nature 369: 684-685 and thereferences cited therein (incorporated by reference herein), in whichPCR amplicons of up to 40 kb are generated. One of skill will appreciatethat essentially any RNA can be converted into a double stranded DNAsuitable for restriction digestion, PCR expansion and sequencing usingreverse transcriptase and a polymerase. See, e.g., Ausubel, Sambrook andBerger, all supra.

The invention is illustrated in the following examples, which areprovided by way of illustration and are not intended to be limiting.

EXAMPLES Example 1 Cloning, Expression, and Purification of P±TrpA andPfTrpB

The genes encoding PfTrpB (UNIPROT ID Q8U093) and PfTrpA (UNIPROT IDQ8U094) were obtained as gBlocks and cloned into pET22(b)+ forexpression in E. coli BL21 E. cloni EXPRESS cells (Lucigen).Heterologous protein expression of PfTrpA and PfTrpB was performed inTerrific Broth with 100 μg/mL ampicillin (TBamp) and induced with 500 mMIPTG (final concentration 1 mM). PfTrpB was purified via a HisTrap HPcolumn. PfTrpA was purified via a Q HP HiTrap column (flow-through),followed by ammonium sulfate precipitation, and hydrophobic interactionchromatography on a phenyl Sepharose HP HiTrap column (FIG. 3).

Library Construction and High-Throughput Screening.

Error-prone PCR libraries were constructed using standard protocols witheither MnCl₂ or Mutazyme II (Stratagene). DNA shuffling andsite-directed mutagenesis by overlap extension (SOE) PCR were performedto recombine activating mutations. The resulting libraries were clonedinto pET22(b)+ with the C-terminal his-tag for expression in E. coliBL21 E. cloni EXPRESS cells. High-throughput expression and screeningwere performed on 96-well scale. Formation of L-tryptophan was recordedat 290 nm.

Kinetics and UV-Vis Spectroscopy.

Data were collected between 550 and 250 nm on a UV1800 Shimadzuspectrophotometer (Shimadzu) using 0.25-20 μM of enzyme in 200 mMpotassium phosphate (pH 8.0) in a quartz cuvette. Samples were incubatedat 75° C. for >3 min to ensure a stable temperature was reached. PfTrpBactivity (kat) was measured by monitoring tryptophan formation at 290 nmusing Δe290=1.89 mM⁻¹·cm⁻¹.

Substrate Selectivity.

The relative rate of NCAA production was measured using 20 mM L-serineand 20 mM indole analog (FIG. 4A) in 200 mM potassium phosphate (pH 8.0)with 5% (vol/vol) DMSO. Reactions were incubated at 75° C. for 1 h,quenched, and the relative rate of production formation was measured bycomparing the ratio of the product peaks measured via ultra HPLC-MS(UHPLC-MS) Agilent 1290 with 6140 MS detector at 280 nm and thennormalizing for the enzyme concentration.

Crystallography.

Crystals of PfTrpB and PfTrpS were grown using the sitting drop vapordiffusion method and cryoprotected before diffraction at the StanfordSynchrotron Radiation Laboratories on beamline 12-2. Ligand boundcrystals of PfTrpB were prepared by soaking preformed crystals with aconcentrated solution of L-Ser or L-Trp. Structures were determined bymolecular replacement and models were built using standard procedures.

Identification of Nonnatural Amino Acid Products.

Preparative-scale reactions were conducted using PfTrpB^(0B2), which wasprepared as a heat-treated lysate. Products were purified directly onC-18 silica, and their identities confirmed by 1H NMR and low-resolutionmass spectrometry (LRMS). The optical purity of the products wasestimated by derivatization with N-(5-fluoro-2,4-dinitrophenyl)alanamide (FDNP-alanamide).

Selection of the Parent Enzyme, TrpB, from Pyrococcus furiosus.

A search was performed for an engineering starting point on knownthermophilic TrpS enzymes for three reasons: (i) higher operatingtemperatures afford increased solubility of the hydrophobic substrates,which is useful for preparative reactions; (ii) thermostable enzymes aremore tolerant to the introduction of activating but potentiallydestabilizing mutations; and (iii) thermostable enzyme variants can bescreened efficiently. A comparison of published kinetic properties ofTrpS from Thermotoga maritima, Thermococcus kodakaraensis, andPyrococcus furiosus let to the selection of Pyrococcus furiosus for itssuperior kinetic parameters and thermostability (Table 1). PfTrpBheterologously expressed and purified from E. coli has a k_(cat) of 0.31s⁻¹ and experiences a 12-fold increase in catalytic efficiency uponaddition of purified P. furiosus TrpA (PfTrpA) to make the PfTrpScomplex (Table 2), similar to values reported previously for E. coliTrpB (EcTrpB). Notably, PfTrpB does not show the mechanism-basedinactivation that inhibits use of StTrpB for preparation of NCAAs.

TABLE 1 Comparison of TrpB thermophilic enzymes k_(cat), K_(M), mMK_(M), μM k_(cat) change Host s⁻¹ L-Ser indole with TrpA Thermalstability indicators Thermotoga maritima 4.2 110 40 2.4 Kineticsmeasured at 80° C. Thermococcus kodakarensis 1.04 ± 0.03 n/a 63 ± 5  3.35% activity after 1 h at 80° C. Pyrococcus furiosus 0.31 ± 0.02 1.2 ±0.1 77 ± 12 3.2 T₅₀ = 94.7 ± 1.2 Values for PfTrpB are those reportedhere; the references supply similar data measured by a different group.n/a, not available.

TABLE 2 Biochemical characterization of tryptophan synthasesk_(cat)/K_(M), mM⁻¹s⁻¹ k_(cat) change with Enzyme Mutations k_(cat), s⁻¹K_(M), mM L-serine K_(M), μM indole indole TrpA* T₅₀ ° C.^(†) PfTrpS —1.0 0.6 20 50 — >95 PfTrpB — 0.31 1.2 77 4 3.2 95 PfTrpB²⁶⁹ T292S 1.10.84 14 78 0.34 95 PfTrpB^(4D11) E17G, I68V, T292S, F274S, T321A 2.2 1.211 200 0.3 84 PfTrpB⁰⁸² P12L, E17G, I68V, T292S, 2.9 0.7 8.7 330 0.04 87F274S, T321A All kinetic data are measured at 75° C. using a previouslydescribed (15) continuous assay for Trp production. Additional mutationsrelative to their parent enzyme are highlighted in bold. *The effect ofPfTrpA was measured by addition of a fivefold stoichiometric excess ofPfTrpA under conditions saturating in each substrate. ^(†)T50 is thetemperature of half-maximal activity after incubation for 1 h.

Directed Evolution of PfTrpB for Stand-Alone Function.

Random mutagenesis was performed by error-prone PCR and a small PfTrpBmutant library (528 clones) was screened for increased Vmax undersaturating concentrations of substrate (L-serine and indole). Theextreme thermostability of the parent enzyme permitted a 1-h heattreatment of the lysates at high temperature (75° C.) that precipitatedthe majority of E. coli proteins and ensured that any activated variantsretained significant stability. Formation of L-tryptophan took place at75° C. for up to 1 h (generation 1, 1 h; generations 2 and 3, 6 min).The reactions were then quenched in an ice-water bath, and theproduction of L-tryptophan was quantified at 290 nm with a plate reader.This procedure identified many activating mutations, with 3.8% (20/528)of the screened variants of generation 1 showing at least 40% greaterproduct formation than the parent. A single mutation, T292S, gave riseto a 3.5-fold increase in k_(cat) compared with PfTrpB, which completelyrecovered k_(cat) and even exceeded the catalytic efficiency(k_(cat)/KM) of the PfTrpS complex (Table 2). Twenty-six other mutationsin 19 different variants also contributed activating effects, includingW2R, G4C, G4D, E5K, Y10H, P12L, V11A, E13G, E17G, K20E, E21V, E23V,F35S, N35S, Y41C, L59Q, K67I, I68V, M123V, I127S, M144T, L146V, N150T,N166D, Y178C, H180R, Y181C, L182P, D220E, M233V, M233I, N267F, G272D,F274S, F274L, D284E, D284G, T292S, T321A, and T323A.

12 of the most activating mutations identified in the first generationwere recombined. Screening a total of 1,408 clones, clone PfTrpB^(4D11)was identified containing mutations E17G, I68V, F274S, T292S, and T321A.The k_(cat) of PfTrpB^(4D11) was 2.2 s⁻¹, a seven-fold improvement overwild type (Table 2). PfTrpB^(4D11) served as template for a final roundof random mutagenesis, for which 1,144 clones were screened. ClonePfTrpB^(0B2) carried one additional mutation (compared to PfTrpB4D11),P12L, and had a k_(cat) that was 9.4-fold higher than PfTrpB andthreefold higher than PfTrpS. PfTrpB0B2 provided an isolated enzymedomain to be as active as in its native complex.

Biochemical Comparison of Evolved PfTrpB Enzymes with PfTrpS.

Kinetic analysis of PfTrpB and PfTrpS established that the 12-foldincrease in the catalytic efficiency for indole upon complexation isdriven by both an increase in k_(cat) and decrease in KM (Table 2).Despite screening the mutant libraries under saturating conditions forboth substrates, a steady decrease was observed in the KM for indole inthe enzymes with greater activity, which mimics the behavior of thenative complex. The KM for L-serine fluctuated during evolution, and inthe final round the values for PfTrpB0B2 and PfTrpS were similar.

Though Michaelis-Menten kinetic analysis provides a simple readout ofoverall catalytic performance, activity changes upon complex formationand during directed evolution are associated with a shift in thepopulations of the intermediates in the TrpB catalytic cycle. The PLPcofactor absorbs in the UV-vis region, and different chemicalintermediates have characteristic peaks that can be measured readily(FIG. 1B). Under turnover conditions, the recorded spectrum reflects theBoltzmann-weighted average of each of the intermediates in the catalyticcycle. Incubation of PfTrpB with L-serine results in a large increase inabsorption at 428 nm, consistent with accumulation of E(Aex1). A peak at320 nm developed over several minutes, whereas the absorption at 428 nmremained constant, which was attribute to the previously characterizedserine deaminase activity that is an artifact of not having a competingnucleophile present. In contrast, L-serine-bound PfTrpS has a Amax near350 nm, consistent with a shift in the equilibrium to populate theE(A-A). With the engineered proteins, the external aldimine absorbanceat 428 nm decreases, and the absorbance bands at 350 nm grow inintensity over the course of directed evolution of Trp synthaseactivity.

Adding purified PfTrpA to each TrpB variant gave a surprising result:instead of enhancing activity (or doing nothing), PfTrpA inhibited eachimproved TrpB, an effect that was stronger with each evolutionary step,to the point where PfTrpB0B2 had just 4% of its activity when PfTrpA wasadded (Table 2).

Structural Analysis of PfTrpB.

Whereas the residues that perform the TrpB chemistry are conservedthroughout evolution, the conformational motions associated withallosteric signaling have not been characterized outside of StTrpS or inthe absence of the α-subunit. A high-resolution structures of wild-typePfTrpB in its ligand-free state, bound to its L-serine substrate, andbound to its L-tryptophan product was obtained (Table 3). Comparison ofthe ligand-free and Ser-bound structures (at 1.69 Å and 2.0 Åresolution, respectively) reveals motion of the COMM domain into apartially closed state upon serine binding, as well as a hydrogen bondbetween Asp300 and the Ser-hydroxyl of E(Aex1). This largeconformational rearrangement is structurally equivalent to thatcharacterized for StTrpS, with 0.5 Å rmsd between the E(Aex1) forms ofTrpB, despite the modest (59%) sequence identity and lack of anα-subunit. Combined with their similar biochemical properties, thisstructural conservation constitutes firm experimental support forapplying insights gleaned from StTrpS and EcTrpS to the function ofPfTrpB. Labeling studies have shown that β-substitution occurs withretention of stereochemistry, indicating the hydroxyl of E(Aex1) mustrotate 180° from its crystallographically observed state to eliminatefrom the same face to which indole is added. The H-bond between E(Aex1)and Asp300 is, therefore, transient during the catalytic cycle andsuggests an important role for the H-bond between Thr292 and Asp300 thatwas observed in the ligand-free structure. Notably, T292S was one of themost activating mutations identified in the first round of directedevolution (Table 2). When L-Ser is incubated with PfTrpB2G9, the UV-visspectrum clearly shows that the equilibrium is shifted toward E(A-A). Itwas hypothesized that this mutation alters the energetics of theAsp300-E(Aex1) interaction to favor the fully closed conformationalstate of the enzyme and thereby accelerate the reaction.

TABLE 3 Crystallographic data collection and refinement statistics.Protein PfTrpB PfTrpB PfTrpB PfTrpS PDB ID code 5DVZ 5DW0 5DW3 5E0KLigand None L-Serine L-Tryptophan None Space group P2₁2₁2₁ P2₁2₁2₁P2₁2₁2₁ P2₁2₁2₁ Cell dimensions, Å a, b, c = 87.1, a, b, c = 84.2, a, b,c = 83.7, a, b, c = 87.7, 111.9, 160.8 109.1, 160.8 108.9, 160.1 225.0,296.2 Cell angles α = β = γ = 90° α = β = γ = 90° α = β = γ = 90° α = β= γ = 90° Data collection Wavelength, Å 0.9795 0.9795 0.9795 0.9795Beamline SSRL 12.2 SSRL 12.2 SSRL 12.2 SSRL 12.2 Resolution, Å   40-1.69  40-2.01   40-1.74   40-2.76 Last bin (Å) (1.72-1.69) (2.05-2.01)(1.77-1.74) (2.81-2.76) No. observations 865,034 942,945 1,455,8511,006,477 Completeness (%) 99.6 (99.9) 98.0 (67.2) 98.7 (75.0) 99.3(93.7) R_(pan) (%) 0.050 (0.899) 0.034 (0.754) 0.020 (0.752) 0.082(1.21)  CC(1/2) 0.995 (0.439) 0.999 (0.299) 1.000 (0.425) 0.990 (0.154)l/σl 7.3 (0.6) 15.1 (0.9)  18.0 (1.0)  8.0 (0.6) Redundancy 4.9 (4.9)9.8 (5.6) 9.8 (2.8) 6.7 (5.3) Refinement Total no of reflections 161,91091,540 140,124 142,144 Total no. of atoms 12,278 11,976 12,282 28,872Final bin (Å) (1.73-1.69) (207-2.01) (1.79-1.74) (2.83-2.76) R_(work)(%) 20.2 (39.1) 17.6 (36.7) 18.9 (36.1) 20.4 (37.7) R_(free) (%) 22.8(39.0) 22.1 (36.8) 22.7 (38.4) 23.8 (39.2) Average B factor, Å² 31.842.7 40.5 Ramachandran plot favored, % 96.8 96.2 96.6 97.3 Allowed, %100 100 99.9 99.8 Outliers, % 0 0 0.1 0.2 Values in parentheses are forthe highest resolution shell. R_(merge) is Σ|lo − l|/Σlo, where lo isthe intensity of an individual reflection, and l is the mean intensityfor multiply recorded reflections; R_(work) is Σ||Fo − Fc||/Fo, where Fois an observed amplitutde and Fc a calculated amplitude; R_(free) is thesame statistic calculated over a 5% subset of the data that has not beenincluded.

The structure of PfTrpB with L-tryptophan bound in the active site at1.74 Å resolution shows the product is not covalently linked to the PLPcofactor, but is in a novel ligand-binding pose (FIG. 5C). ResiduesThr105 to His110 comprise a carboxylate binding motif that also formsH-bonds to the primary amine of L-tryptophan through the backbone N—H ofAla106. This same residue also H-bonds with the Ser-hydroxyl of E(Aex1).Asp300, however, is not observed to interact with L-tryptophan. Ahydrogen bond between Glu104 and the N-1 of L-tryptophan likely alsooccurs when indole binds. This interaction may serve to increase thenucleophilicity of indole by positioning C-3 close to the acrylate ofE(A-A) and by increasing electron density of the arene (FIG. 1B). Glu104is located in the COMM domain and shifts closer to the active site uponclosure (FIG. 5A). In each of the substrate- and product-boundstructures, a rotameric shift of Phe274 and His275 was observed (FIG.6C) that may function as a gate within the indole tunnel (FIG. 6D). Inthe structure of PfTrpS, a hydrogen bond between His275 and Asp43 wasobserved from the α-subunit, indicating that PfTrpA binding stabilizesthis open conformation. In StTrpS, NMR analysis has shown this motion isconcerted, and the observation that it is conserved across species isconsistent with it having an important role for regulating catalyticfunction. The location of the F274S mutation is therefore quitestriking, because it may alter the energetics of this transition tofavor higher activity.

Two mutations, E17G and P12L, map onto the α/β interface of a previouslydetermined 3.0-Å structure of PfTrpS, but this low resolution precludedconfident assessment of the side-chain interactions for these residues.A higher-resolution structure was solved at 2.76 Å that revealed a saltbridge between Glu17 of PfTrpB and Arg148 of PfTrpA. Pro12 of PfTrpB isan evolutionarily conserved residue that lies along the indole tunnelbetween the two subunits, where previous studies have found thatmutation to bulkier residues inhibits substrate channeling. Suchinteractions are clearly disrupted at the α/β interface, but the stronginhibition of PfTrpB0B2 upon PfTrpA addition demonstrates that theseproteins still associate. Two mutations present in PfTrpB0B2, I68V andT321A, are distal to sites that undergo an observable structural changeupon substrate binding or complex formation, and their contribution torate enhancement is difficult to rationalize. Overall, 60% of theactivating mutations identified through random mutagenesis were locatedwithin 5 Å of the α/β interface, the COMM domain, or regions thatundergo observable motion upon transition to the closed conformation.These positions comprise just 31% of the protein sequence, indicatingmodest enrichment within residues in the immediate spatial route betweenthe α/β interface and the β-subunit active site. In contrast to the manymutations that have been identified as deleterious to the allostericcommunication in TrpS, the mutations identified here using directedevolution are the first reported to affect allosteric communication andincrease the activity of TrpB in isolation.

PfTrpB0B2 is a Stand-Alone Catalyst for Production of NCAAs.

The selection of TrpB to evolve for high activity outside of its nativecomplex was motivated by practical considerations. Previous studies haveshown that StTrpS is a promiscuous enzyme, capable of synthesizingdiverse analogs of L-tryptophan. These analogs require subtly differenttransition state stabilization for catalysis, but the role of allosteryin promoting this desirable chemistry has not been studied. Arepresentative panel of substrate analogs was selected to studypromiscuous activity in the native and engineered proteins (FIG. 4A).The StTrpS complex reacts with most halogenated and methylated indoles,which only modestly change the steric and electronic properties of theindole ring and afford reactivity at C3. Alternatively, indazole (5) andindoline (6) (see FIG. 4A), which have substantially altered electronicproperties, react at N1 for C—N bond formation. The relative rate ofPfTrpB compared with PfTrpS was performed and a much larger rateenhancements for TrpB on the indole derivatives than on the nativesubstrate was observed (FIG. 4B), up to a 100-fold increase in the rateof NCAA synthesis with 5-bromoindole (7).

The activity of PfTrpB0B2 was measured on the substrate panel (FIG. 4B)and a substantial increase in activity relative to PfTrpB for allnucleophiles tested was observed. The activity profile is broadlysimilar to that of PfTrpS, with a few exceptions. The PfTrpS complexreacts approximately eight fold faster than PfTrpB0B2 with bromoindole(7), whereas PfTrpB0B2 reacts approximately six fold faster than PfTrpSwith indoline (6) and three fold faster with indazole (5). The identityof each product was confirmed by mass spectrometry and NMR in reactionsusing PfTrpB0B2. Because the screen was for increases in Vmax duringlaboratory evolution, the variants selected also have improvedexpression levels relative to PfTrpB. E. coli cultures produce threefoldmore soluble and active PfTrpB0B2 than PfTrpB, exceeding 230 mg enzymeper liter culture, facilitating preparative reactions and future use ofPfTrpB0B2 as a biocatalyst.

Example 2 Cloning, Expression, and Purification of the DifferentOrthologs

The genes encoding AfTrpB (UNIPROT ID 028672), TmTrpB (UNIPROT IDP50909) and EcTrpB (UNIPROT ID P0A879) were obtained from IDT and clonedinto pET22(b)+ using Gibson Assembly. Protein expression was carried outin E. coli BL21 E. cloni Express cells (Lucigen) by inoculating 10-mLTerrific Broth (with 100 μg/mL ampicillin (TB_(amp))) with a singlecolony and incubated over night at 37° C. and 250 rpm. These overnightcultures were used to scale up to 500-mL TB_(amp) expression cultures,which were grown by shaking at 250 rpm and 37° C. for ˜3 h or until anOD₆₀₀ of 0.8 was reached. Then, after chilling the cultures on ice for20 min, induction was conducted by the addition of IPTG to a finalconcentration of 1 mM. Induced cultures were allowed to grow at 250 rpmand 20° C. for another 20 h. After centrifugation, pelleted cells werefrozen and stored at −20° C. until further use. For proteinpurification, thawed cells were resuspended in 50 mM potassium phosphatebuffer (KPi, pH 8, 20 mM imidazole and 100 mM NaCl (buffer A)), with 200μM PLP. Lysis was performed by adding BugBuster (Novagen) and incubatingfor 15 min at 37° C. Once cells were lysed, they were centrifuged toobtain the soluble protein-rich fraction. In the case of TmTrpB (but notfor AfTrpB or EcTrpB), the lysate was then incubated at 75° C. for 20min and was subjected to another centrifugation step. Afterwards,purification was done using a 1-mL histrap HP column in an AKTA purifierFPLC system (GE Healthcare). A linear gradient was used from buffer A tobuffer B (50 mM KPi, pH 8, 500 mM imidazole and 100 mM NaCl) andproteins eluted at approximately 140 mM imidazole. Purified proteinswere desalted into 50 mM KPi, pH 8, flash-frozen in liquid N₂, andstored at −80° C. until further use.

TmTrpA gene was also obtained from IDT and cloned into pET22(b)+ usingGibson Assembly, but without including the C-terminal His-tag. To obtainTmTrpS, both TmTrpA and TmTrpB were independently expressed in TB_(amp),lysed with BugBuster and incubated at 75° C. Afterwards, an SDS-PAGE gelwas run to check purity and concentration ratio and the lysates weremixed using a final ratio of 1:3 (TrpB:TrpA). A furtherNi-chromatography step was performed, obtaining TmTrpS with a purity ofaround 95%, as checked by SDS-PAGE electrophoresis. To check that thecomplex was present as single species, a purified sample of TmTrpS wasrun in an analytical size exclusion column (Superdex 200 10/300 GL),yielding a single peak. Protein concentrations were determined via theBradford assay (Bio-Rad).

Library Construction.

For TmTrpB, a recombination library of mutations P14L, P19G, I69V,L274S, and T292S was constructed using site-directed mutagenesis byoverlap extension (SOE) PCR. Position 321 was omitted, sincePfTrpB^(0B2) contains an alanine residue, the one that is presentnaturally in TmTrpB. In this library, both the native residue and themutation were allowed at each of the mentioned positions. Themutagenesis primers encoded the mutations and also the correspondingwild-type sequences. Since positions 14 and 19 are very close, they wereincluded on the same mutagenic primer. This way, six fragments weregenerated by using Phusion polymerase. The fragments were then DpnIdigested, gel purified, and used as template for the subsequent assemblyPCR using the flanking primers only. The assembly PCR product was clonedinto pET22(b)+ between restriction sites NdeI and XhoI.

For EcTrpB recombination library, the process was analogous and therecombined mutations were P18G, P23G, L73V, Y279S, and S326A. In thiscase, the omitted position was S297, the corresponding residue to T292in PfTrpB, since it already contains a serine. At this position,PfTrpB^(0B2) contains the mutation T292S (see Example 1, above). For theEcTrpB site saturation library at position S297, three primers weredesigned which only differed at the mutagenic position. They containedcodons NDT (which encodes for Ile, Asn, Ser, Gly, Asp, Val, Arg, His,Leu, Phe, Tyr, and Cys), VHG (which encodes for Met, Thr, Lys, Glu, Ala,Val, Gln, Pro, and Leu) and TGG (Trp), so that all 20 natural aminoacids are included. These three primers were mixed in a 12:9:1 ratioaccording to the 22c-trick. Then, the SOE PCR was performed asdescribed.

Library Screening.

For TmTrpB library screening, BL21 E. cloni Express cells carryingTmTrpB wild type and variant plasmids were grown in 96-well deep wellplates in 300 μL TB_(amp) at 37° C. and 80% humidity with shaking at 250rpm overnight. Then, 630 μL TB_(amp) were inoculated with 20 μL of theovernight cultures and allowed to grow at 37° C. and 80% humidity withshaking at 250 rpm for 3 h. After chilling the cultures on ice for 20min, ITPG was added to a final concentration of 1 mM. Expression wasallowed for another 20 h at 20° C. with shaking at 250 rpm. Cells werethen centrifuged at 4,000 g for 10 min and frozen at −20° C. Forscreening, cells were thawed at room temperature and then subjected tolysis by adding 400 μL/well of 200 mM phosphate buffer, pH 8, with 1mg/mL lysozyme and 0.05 mg/mL DNaseI for 1 h at 37° C. Aftercentrifugation at 5,000 g for 20 min, a 160-μL aliquot of the lysate wastransferred into PCR plates (USA Scientific, Ocala, USA), heat-treatedfor 1 h at 75° C., and then spun again at 1,000 g and 4° C. for 30 min.After the transfer of 40 μL of lysate to a fresh deep well plate, 160 μLof assay buffer (200 mM phosphate buffer, 200 μM indole, 100 mML-serine, pH 8) were added. Reaction was allowed to run for 15 min at75° C. and then stopped after addition of 200 μL of CH₃CN.

Based upon the mutations identified in Example 1, experiments wereperformed to determine if these same/similar mutations could be carriedover to other TrpB homologs. A diverse set of TrpB homologs based on aphylogenetic analysis of TrpB: Archaeoglobus fulgidus (AfTrpB, 72%sequence identity), Thermotoga maritima (TmTrpB, 64%), and Escherichiacoli (EcTrpB, 57%) were selected. A multiple-sequence alignment withPfTrpB (FIG. 2) showed that several of the residues mutated inPfTrpB^(0B2) (for list of mutations see Table 2) were not conservedamong the four homologs, reinforcing the fact that allosteric networksare not well-conserved in evolution, even when activity and structureare conserved (FIG. 7). Indeed, the homologs from Tm and Ec eachcontained a mutation from PfTrpB^(0B2) in their native sequences (A321in TmTrpB and S297 in EcTrpB).

The three TrpB homologs and their corresponding 0B2 variants wereexpressed and purified, and then their kinetic properties (k_(cat) andK_(M) of indole) were measured. AfTrpB^(0B2) exhibited a 7-fold increasein k_(cat) and a 20-fold increase in k_(cat)/K_(M) (Table 4, entry 3)compared to wild type (Table 4, entry 4). Notably, this homolog has thehighest sequence identity with PfTrpB. Since it was proposed that the0B2 mutations mimicked the effects of TrpA-binding for PfTrpB, testswere performed to determine whether AfTrpB^(0B2) was being activatedthrough an analogous mechanism. The UV-vis spectra of the enzymes wasrecorded before and after adding L-serine, relying on the diagnosticspectrum of the PLP cofactor to report the steady state population ofthe catalytic intermediates. After addition of L-serine, the spectrum ofAfTrpB displayed a shift in λ_(max) from 412 nm to 428 nm, indicatingthe formation of the external aldimine with serine, E(Aex₁). Conversely,the spectrum of AfTrpB^(0B2) revealed a shift in λ_(max) to 350 nm,which corresponds to the amino-acrylate intermediate, E(A-A). Thislatter spectrum is almost identical to that of AfTrpS, suggesting thatthe mutations are indeed mimicking the effect of the TrpA-binding andfurther supporting that the 0B2 mutations have a similar effect in bothspecies.

TABLE 4 Kinetic parameters of the Pf and Af homologs. ^([a]) K_(M)k_(cat) /K_(M) k_(cat) (μM (μM⁻¹ s⁻¹ Entry Enzyme (s⁻¹) indole) indole)1 ^([b]) PfTrpB^(0B2) 2.9 8.7 330 2 PfTrpB^(WT) 0.31 77 4.0 3 ^([c])AfTrpB^(0B2) 0.51 4.8 110 4 AfTrpB^(WT) 0.074 12 6.0 ^([a]) Measurementtemperatures were 75° C. for Pf and 60° C. for Af. ^([b]) Contains themutations P12L, E17G, I68V, F274S, T292S, and S321A. ^([c]) Contains themutations (ADD 0B2 mutations)

The next homolog, TmTrpB, was examined. This enzyme already contains the0B2 mutation A321 in its native sequence, but when the other fivemutations were incorporated, the k_(cat) was reduced to just 10% of thewild-type activity (Table 5, entries 1 and 2), suggesting that someresidues' contributions to allosteric signaling had changed throughoutdivergent evolution. To investigate whether a subset of the 0B2mutations would still prove to be activating, or whether the allostericmechanism had fundamentally changed compared to PfTrpB, a recombinationlibrary of the 0B2 mutations in TmTrpB was constructed. Three mutations(P19G, I69V, and T292S) were able to improve activity with respect towild type. Of these the variant with all three mutations was the mostactive, with an 8-fold increased k_(oat) and a 10-fold improvedk_(cat)/K_(M) (Table 5, entry 3). Notably, the T292S mutant by itselfhad a 4-fold increase in k_(cat) and a 6-fold increase in k_(cat)/K_(M)(Table 5, entry 4). Although all combinations of these mutations led toimproved k_(cat) values (FIG. 8) only the variants with T292S gave aUV-vis spectrum with a prominent peak at 350 nm (FIG. 9). The variantswithout the T292S mutation lacked this probative absorbance peak, butthe decrease at 428 nm and concomitant increase at 350 nm are consistentwith a similar, though less pronounced activation.

TABLE 5 Kinetic parameters of activated Tm variants. ^([a]) K_(M)k_(cat) /K_(M) k_(cat) (μM (μM⁻¹ s⁻¹ Entry Enzyme (s⁻¹) indole) indole)1 TmTrpB^(0B2 [b]) 0.11 72 2.0 2 TmTrpBWT 1.3 33 39 3TmTrpB^(triple [c]) 9.8 26 380 4 TmTrpB^(T292S) 5.8 25 230 5 TmTrpS 2.244 50 ^([a]) Measurement temperature was 75° C.. ^([b]) Contains themutations P14L, P19G, I69V, L274S and T292S. ^([c]) Contains themutations P19G, I69V, and T292S.

The primacy of the T292S mutation was also observed in Pf, where thismutation restored the k_(cat) of the isolated PfTrpB to that of thePfTrpS complex. In Tm, this single mutation increased the k_(cat) by3-fold more than TmTrpA binding (Table 5, entry 5). Hence, the samemutations may activate different homologs, but their degree ofactivation is not conserved.

Mutational activation of the most distant homolog, EcTrpB (57%identity), posed an exceptional challenge. A recombination library ofthe 0B2 mutations in EcTrpB yielded no variants with enhanced activityand only a few with similar activity as wild type. Notably, the Thr-Sermutation that has been present in all of the most-active variants wasnot possible for EcTrpB because a serine is natively present at thisposition (S297). Other mutations were tested to determine whether theymay be activating here, but a site-saturation library confirmed thatserine is the optimal residue at that position.

All of the activating mutations for PfTrpB^(0B2) were originallydiscovered from a library of random PfTrpB mutants. Attention was drawnto the PfTrpB double mutant M144T and N166D; not only is this variantalmost as active as PfTrpB^(T292S), but these two residues reside in theregion that mediates communication between TrpA and TrpB (the so-calledCOMM domain). In addition, these residues are almost universallyconserved. It was hypothesized that the effects of mutationalperturbation at these sites might be conserved throughout evolution aswell. Thus, these were transferred into the three homologs and werepleased to see that all variants showed higher k_(cat) values than wildtype (Table 6).

Once again, the degree of activation was different for each of thehomologs, as reflected in their kinetics and the steady statedistribution of intermediates upon addition of L-serine. In particular,the double mutant Pf, Af, and EcTrpB enzymes still accumulated theE(Aex₁) intermediate but mutation of the TmTrpB enzyme, which nativelyaccumulates a mixed population of E(Aex₁) and E(A-A), completely shiftsthe spectrum such that it shows the characteristic amino-acrylatesignal. These data suggest that this double mutation(TmTrpB^(M145T N167D)) is also activating the enzyme through allostericmimicry, and that these effects are conserved throughout evolution.

TABLE 6 Kinetic parameters of homologous double mutants. K_(M) k_(cat)/K_(M) k_(cat) (μM (μM⁻¹ s⁻¹ Entry Enzyme (s⁻¹) indole) indole) 1PfTrpB^(M144T N166T) 0.83 42 20 2 AfTrpB^(M156T N178T) 0.34 11 31 3TmTrpB^(M145T N167T) 3.3 32 100 4 EcTrpB^(M149T N171T) 0.34 18 19 ^([a])Measurement temperatures were 75° C. for Pf and Tm, 60° C. for Af, and37° C. for Ec.

Screens of these variants against challenging substrates were performedto identify variants with activity greater than PfTrpB^(0B2) that couldserve as parents for further evolution. Halogenated tryptophanderivatives comprise a product class of particular interest was used.Not only can halogens have a tremendous effect on a compound'sproperties, such as biological activity, but they can also serve ashandles for further diversification through cross-coupling.Halotryptophans are also useful tools for chemical biology because theycan probe structural features like n-cation interactions and serve asfluorophores to facilitate the study of protein dynamics. As such, theuse of TrpS to synthesize halotryptophans has been investigatedextensively. In previous studies, however, substitution at the5-position of indole with anything larger than fluorine led to adramatic decrease in reactivity. The panel of stand-alone TrpB enzymeswas screened for activity on 5-haloindoles (6, Scheme 1) and observedthat TmTrpB^(M145T N167D) showed unusually high activity in theformation of the corresponding tryptophan derivatives (7, Scheme 1).Thus one can access 5-chloro and 5-bromotryptophan in 75% or greateryields.

Example 3 General

Chemicals and reagents were purchased from commercial suppliers(Sigma-Aldrich, VWR, Chem-Impex International, Alfa Aesar) and usedwithout further purification unless otherwise noted. Multitron shakers(Infors) were used for cell growth. UV-vis spectra were collected on aUV1800 Shimadzu spectrophotometer (Shimadzu). LC-MS data were collectedon an Agilent 1290 UHPLC with 6140 MS detector (Agilent Technologies).

Cloning, Expression, and Purification of PfTrpB.

The gene encoding PfTrpB (UNIPROT ID Q8U093) was previouslycodon-optimized for Escherichia coli and cloned into pET22(b)+ with aC-terminal his6-tag. Expression and purification protocols for the newvariants reported here were analogous to those described above. Briefly,a single colony of E. coli BL21 E. cloni Express cells (Lucigen)harboring the PfTrpB plasmid was used to inoculate a 5 mL culture ofTerrific Broth with 100 μg/mL ampicillin (TB_(amp)) and incubated overnight at 37° C. and 250 rpm. This culture was used to inoculate a 500-mLTB_(amp) expression cultures, which was incubated 250 rpm and 37° C. for˜3 h or until an OD₆₀₀ of 0.8 was reached. Cultures were chilled on icefor 20 min and expression was induced by the addition of 500 mMisopropyl β-D-thiogalactopyranoside (IPTG) to a final concentration of 1mM and continued to grow at 250 rpm and 20° C. for another 20 h. Cellswere harvested at 4° C. and 5000 g for 10 min; the pellets were frozenat −20° C. until further use.

For preparation as a heat treated lysate, frozen cell pellets werethawed at room temperature and resuspended in 50 mM potassium phosphatebuffer, pH 8.0, with 200 μM PLP, 1 mg/mL Hen egg white lysozyme, and0.02 mg/mL DNAse. After vortexing, cells were lysed with BugBuster(Novagen) according to the manufacturer's recommendations, and thecleared lysates were centrifuged at 20,000 g and 4° C. for 10 min. Thelysate was then incubated at 75° C. for 10 min, centrifuged again asdescribed above and buffer exchanged into 50 mM potassium phosphatebuffer pH 8.0, snap-frozen in liquid N2 and stored at −80° C. untilfurther use.

For purification, frozen cell pellets where thawed and treated as abovewith modification of the lysis buffer: 50 mM phosphate buffer, pH 8,with 20 mM imidazole and 100 mM NaCl (buffer A), with 200 μM PLP. Theheat-treated lysate was applied to a 1-mL histrap HP column. Thepurification was performed with an AKTA purifier FPLC system (GEHealthcare). PfTrpB eluted during a linear gradient from buffer A tobuffer B (50 mM phosphate buffer with 500 mM imidazole and 100 mM NaCl,pH 8) at 140 mM imidazole. Purified PfTrpB was desalted into 50 mMphosphate buffer, pH 8, frozen in liquid N2, and store at −80° C. untilfurther use.

Purified protein concentrations were determined via the Bradford assay(Bio-Rad). The concentration of PfTrpB^(2B9) in heat treated lysates wasdetermined by specific activity. Tryptophan formation was monitored at75° C. over 1 min at 290 nm using Δε₂₉₀=1.89 mM⁻¹ cm⁻¹.² The assaybuffer contained 200 mM potassium phosphate pH 8, and 5 μM PLP. Usingpurified PfTrpB^(2B9), we recorded an activity of 0.9 s⁻¹ with 400 μMInd and 20 mM Ser. Using this parameter, 375 mg L⁻¹ of PfTrpB^(2B9)active catalyst were prepared as a heat-treated lysate.

Library Construction.

The error-prone PCR library was constructed with 200, 300 and 400 μMMnCl₂ as the mutagen using the gene for PfTrpB^(4D11) as the parent. Therecombination library of hits found from the random mutagenesis studies(I16V, Q89L, F95L, L182P, Y192H, and V384A) was constructed usingsite-directed mutagenesis by overlap extension (SOE) PCR. The librarywas constructed from fragments that were DpnI digested, gel purified,and used as template for the subsequent assembly PCR using the flankingprimers only. The assembly PCR product served as template for a secondround of PCRs generating the fragments carrying the remaining mutations,followed by the same procedure as described above. Each library wascloned into pET22(b)+ between restriction sites NdeI and XhoI in framewith the C-terminal his-tag for expression in E. coli BL21 E. cloniExpress cells.

High-Throughput Screening.

For high-throughput expression, BL21 E. cloni Express cells carryingPfTrpB^(4D11) and variant plasmids were grown in 96-well deep wellplates in 300 μL TB_(amp) at 37° C. and 80% humidity with shaking at 250rpm overnight. TB_(amp) expression cultures (630 μL) were inoculatedwith 20 μL of the overnight cultures and continued to grow at 37° C. and80% humidity with shaking at 250 rpm for 3 h. Expression was inducedwith the addition of ITPG to a final concentration of 1 mM topre-chilled (20 min on ice-water bath) cultures. The expressioncontinued for another 20 h at 20° C. with shaking at 250 rpm. Cells werethen centrifuged at 4000 g for 10 min and frozen at −20° C. over night.For screening, cells were allowed to thaw at room temperature and thenlysed in buffer consisting of 200 mM phosphate buffer, pH 8, with 1mg/mL lysozyme and 0.05 mg/mL DNaseI. To increase the enzymeconcentration, 350 μL/well was used for the error-prone library and 400μL/well was used for the recombination library. Cells were lysed viaincubation 37° C. for 1 h. After centrifugation at 5000 g for 20 min, a180-μL aliquot of the lysate (160-μL aliquot for recombination) wastransferred into PCR plates (USA Scientific, Ocala, USA), heat-treatedfor 1 h at 75° C., and then spun again at 1,000 g and 4° C. for 30 min.After the addition of 120-μL assay buffer (200 mM phosphate buffer, 20mM indole, 0.75 mM L-threonine, pH 8) to 80 μL of cleared, heat-treatedlysates in UV-transparent assay plates (Evergreen Scientific), theplates were sealed and formation of β-MeTrp took place at 75° C. for upto 45 min (generation 1: 30 min, generation 2: 45 min). The reactionswere then arrested by incubation in an ice-water bath, and the amount ofβ-MeTrp formed was recorded at 290 nm with a plate reader (TecanInfinite M200).

Low enzyme activity in the first generation led to a relatively higherror in the assay (CV 50%) and only the nine hits with activity2.5-fold greater than parent were selected for subsequent sequencing andrescreening. One of the hits was revealed to be the parent sequence andthree contained only silent mutations. Cultures of each hit containingmissense mutations were grown in triplicate on 5 mL scale and expressionand lysis proceeded in the same manner as described in the Cloning,Expression and Purification section above. Reactions using 10 μM proteinas heat-treated lysate (determined by Bradford assay) and 20 mM eachsubstrate were run for 1 h at 75° C. and quenched by dilution to 50%ACN. Samples were analyzed by quantitation of product on HPLC and theincrease in activity relative to parent are shown in Table 7.

TABLE 7 Activity of hits from random mutagenesis library relative toparent Fold Variant Improvement Mutations PfTrpB^(4D11) 1.0 (parent)PfTrpB^(3C7) 1.5 I16V, Q89L PfTrpB^(4H5) 0.9 L182P PfTrpB^(4G1) 2.4 F95LPfTrpB^(4E9) 1.2 V384A PfTrpB^(2A9) 1.3 Y192H Improvement measured asincrease in β-MeTrp formation after 60 min reaction at 75° C..

For the second generation, each of the silent mutations identifiedthrough error-prone were added to the PfTrpB^(4D11) plasmid and theresultant construct was found to have higher expression under the growthconditions of the high-throughput screen, but not when grown at largerscale in a shaking flask. Nonetheless, this construct was used as theparent for the recombination libraries (described above) which werescreened under similar conditions as the random mutagenesis libraries.Many potentially activated proteins were identified from therecombination library but rescreening the top five hits showed only asingle protein, PfTrpB^(2B9) had activity that was greater than the mostactive variant from the random mutagenesis library (Table 8).

TABLE 8 Activity of hits from recombination library relative to parentFold Variant Improvement Mutations PfTrpB^(4G1) 1.0 (parent) F95LPfTrpB^(1B5) 0.3 I16V, F95L, L182P, V384A PfTrpB^(1F4) 0.8 I16V, F95L,Y192H, V384A PfTrpB^(3H2) <0.01 I16V, A93V, F95L, Y192H, V384APfTrpB^(1E4) <0.01 I16V, Q89L, F95L, L182P, V384A PfTrpB^(2B9) 1.7 I16V,F95L, V384A Improvement measured as increase in β-MeTrp formation after90 min reaction at 75° C..

UV-Vis Spectroscopy.

Spectra were collected between 550 and 250 nm on a UV1800 Shimadzuspectrophotometer (Shimadzu) using 20 μM of enzyme in 200 mM potassiumphosphate pH 8.0 in a quartz cuvette. Samples were incubated at 75° C.for >3 min to ensure a stable temperature was reached. Stage I of thereaction was initiated by addition of 20 mM L-threonine, and the spectrawere measured in <15 s to limit production of α-ketobutyrate fromdeamination of L-threonine, which absorbs at 320 nm.

Total Turnover Number (TTN) Determination.

Measurements were made using HPLC and LC-MS instruments. The amount ofTrp formed was measured at 280 nm using a standard curve withtrichlorobenzene as internal standard. Measurement of the UV-absorptionspectrum of β-MeTrp showed an identical spectrum (Figure SN), and thesame curve employed for both products while determining the TTN for thecatalysts engineered for activity with Ser. Later, it was found that theconversion could be measured by monitoring at 277 nm, the isosbesticpoint for the conversion of indole to L-Trp or β-MeTrp, and calculatingthe ratio of product peak to the sum of the substrate and product peaks.This method is insensitive to loading volume and results agreed withmeasurements using a standard curve. This method of TTN determination isaccurate when there are no competing reactions with indole or product,which was observed for the conditions employed here. This same techniquewas used to determine the TTN of the PfTrpB^(2B9) reaction withdifferent nucleophiles. The isosbestic point for the conversion ofsubstrate to product was measured using a time course UV-vis analysis ofthe reaction catalyzed by PfTrpB^(2B9) using L-Ser as the amino acidsource because the reactions are significantly faster than with L-Thrand the β-Me group does not change the absorbance spectrum of theproduct (Table 9). Reactions were set up in triplicate using a totalvolume of 150 μL with 25 mM nucleophile and 250 mM L-Thr in 200 mMpotassium phosphate pH 8.0 in borosilicate glass vials, as plastics canabsorb indoles at high temperatures. Before addition of enzyme, allreagents were transferred into a Coy anaerobic chamber with <1 ppm O₂ torapidly exchange the atmosphere in the headspace of the vials to 95/5%N₂/H₂, which limits competing non-catalytic oxidation of indoles. Enzymewas added in the anaerobic environment with varied catalyst loading toensure a robust product signal in subsequent analysis. Reaction vesselswere capped before being removed from the anaerobic chamber andincubated in a 75° C. water bath for 24 hours. Reactions were quenchedthe next day by addition of 1 volume (150 μL) of 100% ACN, mixing, andallowing to rest at room temperature for 10 min. Quenched solutions werethen diluted 5-fold with 40% ACN in water and analyzed via LC-MS. In allcases, auxiliary peaks that would indicate non-catalytic degradation ofsubstrate were present at only low levels, contributing to <1% of thetotal integration signal for a given wavelength. For 7-azaindole, asecond peak with m/z=220 was observed that was also found in largerscale reactions and whose properties are consistent with an N-alkylatedproduct.

TABLE 9 TTN of β-substitution reaction with L-Thr with differentnucleophiles Isosbestic Catalyst Point Loading Nucleophile (nm) (%) TTNIndole 277 0.01 8200 ± 1600 2-Methylindole 279 0.01 6400 ± 14006-Methylindole 273 0.01 1100 ± 100  4-Fluoroindole 267 0.1 378 ± 8 5-Fluoroindole 282 0.01 1300 ± 280  Indazole 276 0.04 500 ± 40 7-Azaindole 292 0.1 C-alkylation-220 ± 40 N-alkylation-32 ± 3 Activitymeasured via LC-MS and conversion as the ratio of substrate to totalpeak intensity at the isosbestic point after 24 hour reaction at 75° C..

Protein Crystallography.

Identification of PfTrpB crystallization conditions are described above,and crystals routinely grown in as sitting drops against a 1 mLreservoir of 15-25% PEG3350 and 0.1 M Na HEPES pH 7.85 with motherliquor comprised of 1.5 μL of 8.0 mg/mL PfTrpB and 1.5 μL of wellsolution. Ligand-bound structures were determined by soaking crystals ofPfTrpB with 100 mM L-threonine for 2 min. Crystals were cryo-protectedthrough oil immersion in Fomblin Y (Sigma) and flash frozen in liquid N2until diffraction. Diffraction data were collected remotely at theStanford Synchrotron Radiation Laboratories on beamline 12-2. Crystalsroutinely diffracted at or below 2.0 Å and the data were integrated andscaled using XDS and AIMLESS. A resolution cutoff of CC1/2>0.3 wasapplied along the strongest axis of diffraction. These data contributedto model quality as judged by R_(free) in the final bin <0.4. Thestructure was solved using molecular replacement with PHASER, asimplemented in CCP4. The search model comprised a single monomer ofPfTrpB (PDB ID: 5DW3) subjected to 10 cycles of geometric idealizationin Refmac5 and removal of all ligands. Model building was performed inCoot beginning with data processed at 2.4 Å, followed by subsequentinclusion of increasingly higher resolution shells of data with relaxedgeometric constraints. Refinement was performed using REFMAC5. TheMolProbity server was used to identify rotamer flips and to identifyclashes. After the protein, ligand, and solvent atoms were built TLSoperators were added to refinement, which resulted in substantialimprovements in R_(free) for the models. The structure is deposited withPDB ID: 5IXJ (incorporated herein by reference).

Identification β-Methyl Amino Acid Products.

The identities of the amino acid products were confirmed by ¹H NMR andhigh-resolution mass spectrometry (HRMS). Proton NMR spectra wererecorded on a Varian 300 MHz or Brucker 400 MHz spectrometer. Protonchemical shifts are reported in ppm (δ) relative to tetramethylsilaneand calibrated using the residual solvent resonance (DMSO, δ 2.50 ppm;CD₃OD, δ 3.31 ppm; D20, δ 4.79 ppm). Data are reported as follows:chemical shift (multiplicity [singlet (s), doublet (d), doublet ofdoublets (dd), doublet of doublets of doublets (ddd), triplet (t),triplet of doublets (td)], coupling constants [Hz], integration).Fluorine NMR spectra were recorded on a 300 MHz (282 MHz) spectrometerwithout proton decoupling. Fluorine chemical shifts are reported in ppmrelative to FCCl₃ (δ 0.00 ppm) and were calibrated automatically by thespectrometer using the solvent deuterium lock signal. High-resolutionmass spectra were obtained using fast atom bombardment JMS-600H HighResolution Mass Spectrometer (JEOL).

Reaction with Heat-Treated Lysate:

Reactions were conducted using PfTrpB^(2B9), which was prepared byheat-treatment as described above. The protein was used as a solution inpotassium phosphate buffer (50 mM, pH 8.0) and the concentration variedbetween preps between 97 μM and 670 μM, as determined by specificactivity. Threonine was added as a solid and PLP was used as a 15 mMaqueous solution.

Generally, reactions were conducted in 2-3 mL volume with the followingreagents added sequentially: 0.1 M indole analog, 1.0 M threonine, 0.2 Mpotassium phosphate buffer pH 8.0 with 5% dimethyl sulfoxide, and afive-fold molar excess of PLP to enzyme. Finally, the enzyme solutionwas added and the vial was capped and immersed in a water bath that hadbeen equilibrated to 75° C. After 16-24 h, the reaction mixture wasallowed to cool to room temperature, then purified directly on C-18silica (20 mL column volume) using a Isolera automated column instrument(Biotage) with 0% to 100% acetonitrile/H₂O.

To identify the best parent enzyme for optimization, we first measuredproduction of β-MeTrp using purified enzymes from each generation in theevolution if PfTrpB^(0B2). Wild-type PfTrpB was an inefficient catalyst,performing just 66 turnovers in 24 hours (Table 10, entry 1). Thisactivity was enhanced approximately 6-fold with the single pointmutation T292S (Table 10, entry 2), and further to −420 TTN with theenzyme PfTrpB^(4D11) (Table 10, entry 3), which incorporates fouradditional mutations. However, PfTrpB^(0B2), which has higher Trpsynthase activity than PfTrpB^(4D11) exhibited a decrease in activity(Table 10, entry 4) and we therefore selected PfTrpB^(4D11) as theparent for subsequent evolution.

TABLE 10 Total turnovers catalyzed by TrpB enzymes prior to evolutionfor activity with L-threonine. Entry Enzyme Turnovers 1 PfTrpB^(WT) 66 2PfTrpB^(T292S) 420 3 PfTrpB^(4D11) 660 4 PfTrpB^(0B2) 180 Activitymeasured using 1 μM purified enzyme in 0.2M potassium phosphate bufferpH 8.0 with 20 mM of each reactant, L-threonine and indole, with a 24 hreaction at 75° C..

Previous studies have shown that the catalytic activity of TrpB isgoverned by open-close transitions of the communication (COMM) domain,and mutations that alter this dynamic in the reactivated subunits aredistributed throughout the protein structure. As such, randommutagenesis was applied for the first round of evolution for activity onThr. To determine an optimal mutational load, the retention of functionof 352 clones was measured with different mutation rates. In thisprocess, six missense mutations were identified in five clones with atleast a 2-fold increase in V_(max), obviating the need for screening amore expansive library. The most active clone from this library,PfTrpB^(4G1), increased activity ˜3.8-fold and contained the singlemutation F95L, which abuts the COMM domain. Notably, the enzymePfTrpB^(3C7) contained two mutations, I16V and Q89L, of which the formeris adjacent to the E17G mutation already present in the parent enzyme.The six missense mutations found to be activating for activity on Thrwere subjected to recombination, which resulted in the final variantPfTrpB^(2B9). Three mutations, F95L, I16V, and V384A were retained inthis enzymes, which is eight mutations away from wild-type and has atleast a 6,000-fold boost in productivity. This increase is, in part, dueto an increase in expression of soluble protein from −80 mg PfTrpB per Lmedia, to ˜350 mg of PfTrpB^(2B9), indicating at least a 1,400-foldincrease in catalytic efficiency with Thr.

To assess the molecular basis of this new activity, UV-vis spectroscopywas used, which reports on the steady state distribution of thePLP-bound intermediates in the catalytic cycle. When Ser is added toPfTrpB in its open conformation, λ_(max) shifts from 412 nm to 428 nm,corresponding to transimination of the lysine-bound internal aldimine,E(Ain), to a Ser-bound external aldimine, E(Aex₁). However, addition of20 mM Thr to PfTrpB did not result in any spectral shift indicative ofThr binding. This experiment, however, cannot rule out that Thr bindsnon-covalently and that E(Aex₁) is simply no longer favored. Thr wassoaked into crystals of PfTrpB and diffraction yielded a 1.54-Åstructure that clearly shows Thr does indeed bind non-covalently. TheThr hydroxyl forms a 2.7-Å hydrogen bond with the sidechain of Asp300,an interaction that is also observed in the Ser external aldimine.Modeling of a hypothetical Thr external aldimine that maintains theAsp300 hydrogen bond reveals a strong steric clash between the Thrmethyl group and the backbone carbonyl of Gly298, accounting for thelack of E(Aex₁) observed by UV-vis spectroscopy.

UV-vis spectroscopy was used to probe the basis for enhanced activitythrough directed evolution and addition of 20 mM Thr to each generationof engineered proteins resulted in a clear trend. The 412 nm peakdecreases while a new absorbance band at 350 nm with a broad shoulderout to 550 nm appears, consistent with accumulation of the electrophilicamino acrylate species E(A-A). A similar phenomenon was observed withthe directed evolution for independent TrpB function, however comparisonof the Ser- and Thr-bound PfTrpB^(4D11) spectra clearly indicate thatthe E (Aex₁) and E (A-A) with Thr are much less stable.

The engineered PfTrpB^(2B9) enzyme has several desirable features as acatalyst for β-MeTrp production. It is robustly expressed in E. coli,can be prepared in a moderately pure form as a heat-treated lysate, andits thermal stability permits high reaction temperatures, routinely upto 75° C., which greatly increases the solubility of hydrophobicsubstrates. However, in reactions with one equivalent each of indole andThr, only 44% conversion to product, corresponding to 2220 turnovers wasobserved. A clue explaining this low conversion came from UV-visspectroscopy, which revealed that addition of Thr to PfTrpB^(2B9)results in a time-dependent increase in absorbance at 320 nm, while theremainder of the spectrum remains constant. This was attributed toα-keto butyrate production from the well-described deamination reactionthat results when a nucleophile does not add into C-β and E(Ain) isreformed through transimination. The precise timing of the subsequentsteps is unknown, but the net effect is an abortive reaction wherein theamino acrylate hydrolyses to form α-keto butyrate and ammonium. Thus,additional equivalents of Thr was added to the β-substitution reactionwith indole, which enabled complete conversion of indole to β-MeTrp andup to 8,200 total turnovers.

With these reaction conditions in hand, a characterization of thesubstrate scope of the reaction with Thr was performed. A small panel ofindole-like nucleophiles were screened for reaction with PfTrpB^(0B2)and Ser, and a significant boosts in activity was observed. This wasexpanded on this panel of nucleophiles and tests for activity withPfTrpB^(2B9) using an excess of Thr was performed. Reactions were run tointermediate yield to determine the TTN with a given nucleophile and theidentity of the products was established with a separatepreparative-scale reaction using 100 mM nucleophile, 1.0 M Thr, and0.02-0.25 mol % PfTrpB^(2B9) catalyst. Good reactivity was observed withthe 2-methyl and 6-methyl indole substrates, and decreases in TTNcompared to indole demonstrate the active site is sensitive to stericperturbations. To probe the role of electronic effects on the C—C bondforming step, activity was tested with 4-fluoro and 5-fluoroindole,which are more closely isosteric with indole but have decreased electrondensity in the n-system. Product formation with each substrate and3.4-fold decreased TTN with the 4-fluoro substrate was observed, whichis more electron withdrawing at C-3 than the 5-fluoro substituent. Theincreased steric constraints of the activity site were again clear, asno activity with the 5-chloro-, 5-bromo, and 6-hydroxyindoles, whichundergo reaction with Ser, was observed. A productive reaction wasobserved with 7-azaindole, which is a substantially weaker nucleophilethan indole, and fewer turnovers were observed. Interestingly, a secondproduct was detected in the reaction with 7-azaindole that was assignedas an N-alkylated product. This regioselectivity is well known with theindazole, which we found reacts exclusively to form the N-alkylatedproduct. Surprisingly, no product formation with indoline was observed,which is a stronger nucleophile than indazole or indole and reactssignificantly faster in the reaction with Ser. S-alkylation was alsotested using thiophenol and benzyl mercaptan and activity was observedwith each substrate, but with low turnover and a conspicuous whiteprecipitate in the reaction. Analysis revealed a late eluting peak inthe LC-MS that did not ionize, indicative of oxidative dimerization ofthe substrate. Inclusion of DTT reduced this side reaction.

The data demonstrate that the disclosure provides a new, non-naturalenzymatic route for the biocatalytic production of (2S, 3S)-β-MeTrp.This activity lies in the β-subunit of TrpS, which was subsequentlyengineered for increased activity with Thr as the amino acid donor. Thedevelopment of the resultant catalyst, PfTrpB^(2B9), was greatlyfacilitated by previous efforts to simplify the native two-enzyme systemand the engineered proteins have high thermal stability and expressionin E. coli, enhancing their utility as practical biocatalysts. Thisenzymatic route to β-MeTrp is dramatically shorter than previoussynthetic routes, and also the native 3-enzyme step to this naturalmetabolite. This highlights the capability of protein engineering toquickly produce complicated molecules from simple precursors, and offersa simple and expandable route for the production of β-methyl ncAAanalogs for future studies.

A number of embodiments of the invention have been described.Nevertheless, it will be understood that various modifications may bemade without departing from the spirit and scope of the invention.Accordingly, other embodiments are within the scope of the followingclaims.

What is claimed is:
 1. A recombinant polypeptide selected from the groupconsisting of: (a) a polypeptide comprising a sequence that is at least57% identical to SEQ ID NO:2 and comprises an activating mutation atresidues corresponding to residue 144 and 166 of SEQ ID NO:2, whereinthe polypeptide can catalyze the production of tryptophan or anon-canonical amino acid or unnatural amino acid from an indole orindole derivative and L-serine or L-threonine independent of any othertryptophan synthase subunit; (b) a polypeptide comprising a sequencethat is at least 60% identical to SEQ ID NO:2 and having at least oneactivating mutation including a mutation corresponding to residue 292,wherein the polypeptide can catalyze the production of tryptophan or anon-canonical amino acid or unnatural amino acid from an indole orindole derivative and L-serine or L-threonine independent of any othertryptophan synthase subunit.
 2. The recombinant polypeptide of claim 1,wherein the mutation corresponding to residue 292 is a T→S mutation. 3.The recombinant polypeptide of claim 1, wherein the polypeptide that isat least 60% identical to SEQ ID NO:2 comprises a polypeptide that has asequence of SEQ ID NO:4 or 6, and wherein SEQ ID NO:4 has a mutation atposition 303 and wherein SEQ ID NO:6 has a mutation at position
 292. 4.The recombinant polypeptide of claim 3, wherein the mutations at 303 and292 are T303S and T292S, respectively.
 5. The recombinant polypeptide ofclaim 4, wherein the polypeptide comprises one or more additionalmutations at residues: (i) 12, 17, 68, 274, and 321 of SEQ ID NO:2; (ii)25, 30, 80, 285 and 332 of SEQ ID NO:4; and (iii) 14, 19, 69, and 274 ofSEQ ID NO:6.
 6. The recombinant polypeptide of claim 5, wherein thepolypeptide comprises the following residues at the following positions,wherein at least one position identified in (i)-(iii) is: substitutingan L at position 12, 25, or 14, of SEQ ID NO:2, 4, or 6, respectively;and/or substituting G at position 17, 30, or 19 SEQ ID NO:2, 4, or 6,respectively; and/or substituting a V at position 68, 80, or 69 of SEQID NO:2, 4, or 6, respectively; and/or substituting S or L at position274, 285, or 274 of SEQ ID NO:2, 4, or 6, respectively; and/orsubstituting S at position 292, 303, or 292 of SEQ ID NO:2, 4, or 6,respectively; and/or substituting A at position 321 or 332 of SEQ IDNO:2 or 4, respectively.
 7. The recombinant polypeptide of claim 1 or 3,wherein the polypeptide comprises one or more additional mutationscorresponding to a residue selected from the group consisting of residue2, 4, 5, 10, 11, 13, 16, 20, 21, 35, 36, 41, 59, 67, 89, 95, 123, 127,144, 146, 150, 166, 178, 180, 181, 182, 220, 233, 267, 272, 284, 323,384 and any combination thereof of SEQ ID NO:2.
 8. The recombinantpolypeptide of claim 1, wherein the polypeptide comprises (i) a sequenceof SEQ ID NO:10 that include up to 50, 25, 10, or 5 conservative aminoacid substitutions excluding residues 292 of SEQ ID NO:10; or (ii) asequence that is at least 80%, 90%, 95%, 98%, or 100% identical to SEQID NO:10 and comprises an S at position
 292. 9. The recombinantpolypeptide of claim 1, wherein the polypeptide comprises (i) a sequenceof SEQ ID NO:12 that include up to 50, 25, 10, or 5 conservative aminoacid substitutions excluding residues 12, 17, 68, 274, 292 and 321 ofSEQ ID NO:12; or (ii) a sequence that is at least 80%, 90%, 95%, 98%, or100% identical to SEQ ID NO:12 and comprises the following amino acidsresidues: L12, G17, V68, S292, S274 and A321.
 10. The recombinantpolypeptide of claim 1, wherein the polypeptide comprises (i) a sequenceof SEQ ID NO:14 that include up to 50, 25, 10, or 5 conservative aminoacid substitutions excluding residues 17, 68, 95, 274, 292 and 321 ofSEQ ID NO:14; or (ii) a sequence that is at least 80%, 90%, 95%, 98%, or100% identical to SEQ ID NO:14 and comprises the following amino acidsresidues: G17, V68, L95, S274, S292 and A321.
 11. The recombinantpolypeptide of claim 1, wherein the polypeptide comprises (i) a sequenceof SEQ ID NO:16 that include up to 50, 25, 10, or 5 conservative aminoacid substitutions excluding residues 17, 68, 274, 292, and 321 of SEQID NO:16; or (ii) a sequence that is at least 80%, 90%, 95%, 98%, or100% identical to SEQ ID NO:16 and comprises the following amino acidsresidues: G17, V68, S274, S292 and A321.
 12. The recombinant polypeptideof claim 1, wherein the polypeptide comprises (i) a sequence of SEQ IDNO:18 that include up to 50, 25, 10, or 5 conservative amino acidsubstitutions excluding residues 16, 17, 68, 95, 274, 292, 321 and 384of SEQ ID NO:18; or (ii) a sequence that is at least 80%, 90%, 95%, 98%,or 100% identical to SEQ ID NO:18 and comprises the following aminoacids residues: V16, G17, V68, L95, S274, S292, A321 and A384.
 13. Therecombinant polypeptide of claim 1, wherein the polypeptide comprises(i) a sequence of SEQ ID NO:20 that include up to 50, 25, 10, or 5conservative amino acid substitutions excluding residues 144 and 166 ofSEQ ID NO:20; or a sequence that is at least 80%, 90%, 95%, 98%, or 100%identical to SEQ ID NO:20 and comprises the following amino acidsresidues: T144 and D166.
 14. The recombinant polypeptide of claim 1,wherein the polypeptide comprises (i) a sequence of SEQ ID NO:22 thatinclude up to 50, 25, 10, or 5 conservative amino acid substitutionsexcluding residues 25, 30, 80, 285, 303, and 332 of SEQ ID NO:22; or(ii) a sequence that is at least 80%, 90%, 95%, 98%, or 100% identicalto SEQ ID NO:22 and comprises the following amino acids residues: L25,G30, V80, S285, S303 and A332.
 15. The recombinant polypeptide of claim1, wherein the polypeptide comprises (i) a sequence of SEQ ID NO:24 thatinclude up to 50, 25, 10, or 5 conservative amino acid substitutionsexcluding residues 156 and 178 of SEQ ID NO:24; or (ii) a sequence thatis at least 80%, 90%, 95%, 98%, or 100% identical to SEQ ID NO:24 andcomprises the following amino acids residues: T156 and D178.
 16. Therecombinant polypeptide of claim 1, wherein the polypeptide comprises(i) a sequence of SEQ ID NO:26 that include up to 50, 25, 10, or 5conservative amino acid substitutions excluding residues 292 of SEQ IDNO:26; or (ii) a sequence that is at least 80%, 90%, 95%, 98%, or 100%identical to SEQ ID NO:26 and comprises an S at position
 292. 17. Therecombinant polypeptide of claim 1, wherein the polypeptide comprises(i) a sequence of SEQ ID NO:28 that include up to 50, 25, 10, or 5conservative amino acid substitutions excluding residues 19 of SEQ IDNO:28; or (ii) a sequence that is at least 80%, 90%, 95%, 98%, or 100%identical to SEQ ID NO:28 and comprises an G at position
 19. 18. Therecombinant polypeptide of claim 1, wherein the polypeptide comprises(i) a sequence of SEQ ID NO:30 that include up to 50, 25, 10, or 5conservative amino acid substitutions excluding residues 19 and 292 ofSEQ ID NO:30; or (ii) a sequence that is at least 80%, 90%, 95%, 98%, or100% identical to SEQ ID NO:30 and comprises the following amino acidsresidues: G19 and S292.
 19. The recombinant polypeptide of claim 1,wherein the polypeptide comprises (i) a sequence of SEQ ID NO:32 thatinclude up to 50, 25, 10, or 5 conservative amino acid substitutionsexcluding residues 19 and 69 of SEQ ID NO:32; or (ii) a sequence that isat least 80%, 90%, 95%, 98%, or 100% identical to SEQ ID NO:32 andcomprises the following amino acids residues: G19 and V69.
 20. Therecombinant polypeptide of claim 1, wherein the polypeptide comprises(i) a sequence of SEQ ID NO:34 that include up to 50, 25, 10, or 5conservative amino acid substitutions excluding residues 19, 69 and 292of SEQ ID NO:34; or (ii) a sequence that is at least 80%, 90%, 95%, 98%,or 100% identical to SEQ ID NO:34 and comprises the following aminoacids residues: G19, V69 and S292.
 21. The recombinant polypeptide ofclaim 1, wherein the polypeptide comprises (i) a sequence of SEQ IDNO:36 that include up to 50, 25, 10, or 5 conservative amino acidsubstitutions excluding residues 145 and 167 of SEQ ID NO:36; or (ii) asequence that is at least 80%, 90%, 95%, 98%, or 100% identical to SEQID NO:36 and comprises the following amino acids residues: T145 andD167.
 22. The recombinant polypeptide of claim 1, wherein thepolypeptide comprises (i) a sequence of SEQ ID NO:38 that include up to50, 25, 10, or 5 conservative amino acid substitutions excludingresidues 69 and 292 of SEQ ID NO:38; or (ii) a sequence that is at least80%, 90%, 95%, 98%, or 100% identical to SEQ ID NO:38 and comprises thefollowing amino acids residues: V69 and S292.
 23. The recombinantpolypeptide of claim 1, wherein the polypeptide comprises (i) a sequenceof SEQ ID NO:40 that include up to 50, 25, 10, or 5 conservative aminoacid substitutions excluding residues 149 and 171 of SEQ ID NO:40; or(ii) a sequence that is at least 80%, 90%, 95%, 98%, or 100% identicalto SEQ ID NO:40 and comprises the following amino acids residues: T149and D171.
 24. An isolated nucleic acid encoding the polypeptide of claim1 or
 3. 25. A vector comprising the nucleic acid molecule of claim 24.26. The vector of claim 25, which is an expression vector.
 27. A hostcell transfected with an isolated nucleic acid of claim
 24. 28. A hostcell transfected with a vector of claim
 25. 29. A method for producingtryptophan, a non-canonical amino acid and/or a unnatural amino acidcomprising contacting an indole or indole analog and L-serine orL-threonine with a polypeptide of claim 1 or
 3. 30. A method forproducing a β-methyl-tryptophan or analog thereof, the methodcomprising: (a) providing L-threonine, an indole or indole analog and apolypeptide of claim 1; and (b) admixing the components of (a) in areaction for a time and under conditions to produce theβ-methyl-tryptophan or analog thereof.
 31. The method of claim 30,wherein the indole analog is a compound according to Formula I:

wherein X₁-X₇ are independently either a carbon, nitrogen, oxygen, orsulfur; R₁-R₇ are each independently selected from the group consistingof H, —OH, alkyl, aryl, alkoxy, alkenes, alkynes, and substitutions ofthe foregoing, sulfur-containing group, nitrogen-containing groups,oxygen-containing group, or halogen.
 32. The method of claim 31, whereinthe indole analog is selected from the group consisting of:


33. The method of claim 30, wherein the β-methyl-tryptophan or analogthereof is selected from the group consisting of:

wherein X₁-X₇ are independently either a carbon, nitrogen, oxygen, orsulfur; R₂-R₇ are each independently selected from the group consistingof H, —OH, alkyl, aryl, alkoxy, alkenes, alkynes, and substitutions ofthe foregoing, sulfur-containing group, nitrogen-containing groups,oxygen-containing group, or halogen.
 34. The method of claim 33, whereinthe β-methyl-tryptophan or analog thereof is selected from the groupconsisting of: